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ABSTRACT 
 
During viral infection, a major innate host defense mechanism is to reduce global protein 
synthesis by phosphorylation of eukaryotic translation inhibition factor 2a (eIF2a). eIF2a is 
phosphorylated by four different cellular kinases, protein kinase R (PKR), general control 
nonderepressible 2 (GCN2), PKR-like endoplasmic reticulum kinase, and heme-regulated 
inhibitor, each responding to a different cellular stress. GCN2, which phosphorylates eIF2a in 
response to amino acid starvation, UV irradiation, and oxidative stress, can also phosphorylate 
eIF2a in response to viral infection. PKR senses double-stranded RNA produced by virus 
infection. Many viruses have methods of inhibiting PKR activation or its downstream effects, 
thus circumventing protein synthesis shutdown. These methods include sequestering double-
stranded RNA or producing proteins that bind to and inhibit PKR activation.  
Here we describe our finding that PKR was antiviral in mouse adenovirus type 1 
(MAV-1) infection. We also showed that in multiple cell types, PKR was depleted during 
MAV-1 infection. Inhibiting the proteasome reduced the PKR depletion seen in MAV-1-infected 
cells, indicating that proteasomal degradation is responsible for PKR degradation during MAV-1 
infection. Time course experiments showed that the degradation occurred early after infection. 
Infecting cells with UV-inactivated virus prevented PKR degradation, whereas inhibiting viral 
DNA replication did not. Together these results suggest that an early viral gene is responsible for 
the degradation. Degradation of PKR is a rare mechanism to oppose PKR activity, and it has 
	 xiii	
only been described in six RNA viruses. To our knowledge, this is the first example of a DNA 
virus counteracting PKR by degrading it.  
In addition to PKR being degraded by MAV-1 during infection, we tested whether GCN2 
plays an antiviral role, as seen for several other viruses. Here we describe that GCN2-/- deficient 
(atc) mice and peritoneal macrophages were significantly more susceptible to infection by 
MAV-1. However, atc mouse embryonic fibroblasts had similar viral yields compared to wild 
type mouse embryonic fibroblasts, suggesting that there is a cell-type specific antiviral effect of 
GCN2. There were no differences in viral yields in infected organs of atc mice at 8 days post 
infection compared to wild type organs, except for the cecum, indicating that the difference in 
survival between atc and wild type mice is not likely a result of increased viremia in atc mice. 
There was also no significant difference in histology of organs from MAV-1-infected atc and 
wild type mice. However, cytokine analysis showed that MAV-1-infected atc mice had 
significantly higher levels of interleukin 1a, interleukin 1b, and interferon g in the brain 
compared to infected wild type mouse brains at 7 days post infection, suggesting that a 
difference in inflammatory response could be responsible for the decreased survival of atc mice 
in response to MAV-1 infection. Determining how GCN2 affects the immune response to 
MAV-1 infection could provide insight into how GCN2 is playing an antiviral role in DNA virus 
infection. 
	 1 
 
 
 
Chapter I  
Introduction 
 
Adenoviruses 
 Adenoviruses are non-enveloped double-stranded (ds) DNA viruses that have an 
icosahedral shape and replicate in the nucleus. Within the Adenoviridae family, there are five 
genera, encompassing hundreds of different adenoviruses that infect almost every vertebrate 
species (1). Depending on the serotype, human adenoviruses (hAds) can cause upper respiratory, 
ocular, or gastrointestinal tract infections (1, 2). In immunocompromised patients, hAd infections 
can also result in viral encephalitis, hepatitis, myocarditis, and pneumonia (2). Adenoviruses are 
generally species-specific, with productive infections limited to the natural host (1). Thus, little is 
known about how hAds cause such severe complications, because there is a lack of a good small 
animal models of hAd infection. Mouse adenovirus type 1 (MAV-1) provides a good model to 
study adenovirus pathogenesis. It has some features in common with hAd pathogenesis, for 
example, it causes similar disseminated infection and encephalitis in immunocompromised mice 
(3-5) as well as maintaining a similar persistence after acute infection (6-8). MAV-1 infects brain 
endothelial cells, astrocytes, microglia, monocytes, and macrophages (9) and causes a 
breakdown of the blood-brain barrier by reducing the number of tight junction proteins expressed 
on brain endothelial cells (10). This breakdown in the blood-brain barrier allows leukocytes to 
infiltrate, and it leads to viral encephalitis. Viral encephalitis is associated with increased levels 
	 2 
of cytokines and chemokines, including MCP-1, IL-6, IL-1a, IL-1b, and IL-10 (11). During 
MAV-1 infection, IL-1 plays an important role and without it, IFN-b signaling can lead to 
increased neuroinflammation (12). MAV-1 infection also triggers an adaptive immune response 
in T-cells and B-cells (13, 14). Mice deficient in T- and/or B-cells are highly susceptible to 
MAV-1 infection (13-16); B-cells are important to prevent dissemination of the virus within 
mice due to the production of early T-cell-independent neutralizing antibody and antiviral 
immunoglobulin M (13). T-cells contribute to acute immunopathology and to long term control 
of MAV-1 infection (14). 
 Adenovirus infection can be classified into six stages (Fig. 1.1) (17). First, the adenovirus 
binds to receptors on the outside of the cell using the fiber knobs (18). The virus is then 
endocytosed by the cell and the virion sheds the fiber proteins and escapes the endosome (19). 
Once the adenovirus has escaped the endosome and reached the nucleus, the viral DNA is 
injected into the nucleus, and transcription of early genes by the host polymerase II begins (19, 
20). After the synthesis of early proteins, viral DNA replication begins in the nucleus. Next, 
transcription of late viral genes begins and late viral proteins are translated. Once late viral 
proteins have been produced, the virions can be assembled (21). After the virion is matured, it 
escapes the cell. 
 The adenovirus genome is transcribed from both DNA strands (Fig. 1.2). The early genes 
are expressed prior to viral DNA replication, and the late genes are produced once the viral DNA 
has been replicated (22). The early genes, E1, E2, E3, and E4 are categorized into four groups 
based on the locations of the promoters (23). The late genes largely consist of structural proteins 
and are divided into five groups, L1-L5, and include proteins encoding hexon, penton base, fiber,  
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Figure 1.1 Adenovirus life cycle. (1) The adenovirus virion binds to receptors on the outside of the cell and 
is endocytosed into the cell. (2) The virion sheds fiber proteins and escapes the endosome. (3) Viral DNA is 
injected into the nucleus (green). (4) Early viral genes are transcribed (orange) and early viral proteins are 
translated. (5) Viral DNA is replicated in the nucleus. (6) Late viral genes are transcribed (blue) and late 
viral proteins are translated. (7) New virions are assembled. (8) New virions escape the cell.
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Figure 1.2 MAV-1 genome structure. The adenovirus genome is divided into early genes and late genes. 
Early genes (E1, E3, E4, and E2 genes encoding DNA polymerase [DNA pol], the precursor of the terminal 
protein [pTP], and the DNA binding protein [DBP]) are produced before viral DNA replication, and late 
genes (52/55K, pIIIa, penton, pVII, V, pX, pVI, hexon, proteinase, 100K, 33K, pVIII, fiber, and IVa2) are 
produced after viral DNA replication.
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and core proteins (24-26). Transcription of these late genes is driven by the major late promoter, 
which is about 16.8 map units from the left end of the genome in hAd (27, 28) and each late 
mRNA contains the same 5' untranslated region called the tripartite leader, which enhances 
translation of these genes during infection (29, 30).  
 
Translation control by eIF2a kinases 
 Translation control in the cell involves eukaryotic translation initiation factor 2a (eIF2a) 
(Fig. 1.3). eIF2a functions as part of the initiation complex during translation by forming a 
ternary complex with Met-tRNA and GTP in a reaction catalyzed by eIF2B (31). This complex 
then binds to the 40S ribosome subunit to form a pre-initiation complex. When eIF2a is 
phosphorylated on serine residue 51 (specific residue for human eIF2a) by an eIF2a kinase 
(purple oval, Fig. 1.3), eIF2a forms a stable complex with eIF2B instead of Met-tRNA, leading 
to a reduction in protein synthesis (7, 32-34).  
 The cell is able to respond to specific stresses and inhibit translation through four eIF2a 
kinases that phosphorylate eIF2a in response to different stimuli. These kinases, protein kinase R 
(PKR), heme-regulated eIF2a kinase, general control nonderepressible 2 (GCN2), and PKR-like 
endoplasmic reticulum kinase, all share homology in their kinase domains, but have unique 
activation domains (35-40). PKR functions as part of the innate immune system, becoming 
activated when it binds to dsRNA produced by viruses (41-43); heme-regulated eIF2a kinase is 
primarily expressed in erythrocytes and is activated by low levels of heme within the cell (44); 
PKR-like endoplasmic reticulum kinase is a transmembrane kinase that is activated by 
endoplasmic reticulum stress (35); and GCN2 senses uncharged tRNA and becomes activated 
under amino acid starvation conditions, UV irradiation, and oxidative stress (45, 46). PKR also  
	 6 
 
 
 
 
 
Figure 1.3 Translation control by eIF2α. Translation factor eIF2α forms a ternary complex with GTP and a 
Met-tRNA in a reaction catalyzed by eIF2B. This complex binds to the 40S ribosomal subunit to form a pre-
initiation complex that scans to the initiator AUG, and with GDP hydrolysis, binds the 60S subunit, leading 
to translation. When eIF2α is phosphorylated by an eIF2α kinase, it forms a stable complex with eIF2B and 
no longer forms a pre-initiation complex, leading to a reduction in translation.
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can contribute to the establishment of the antiviral state in some viral infections by indirectly 
stabilizing type I interferon mRNAs (47). 
 
Protein degradation within the cell 
 While the eIF2a kinases affect protein production through translational control, the 
lysosomal and proteasomal degradation pathways modulate protein degradation. Lysosomes are 
membrane-bound organelles that contain various digestive enzymes (48). Proteins can enter the 
lysosome through chaperone-mediated autophagy, the fusion of an autophagosome with the 
lysosome (macroautophagy), or by invagination of the lysosomal membrane to specifically 
uptake cytosolic proteins (microautophagy) (Fig. 1.4) (49). Most proteins, however, are degraded 
by the ubiquitin-proteasome pathway (50).  
 Proteasomal degradation generally involves modification of the protein to be degraded by 
ubiquitin. Ubiquitin is a highly conserved, 76-residue protein that is conjugated to proteins using 
three distinct enzymes (Fig. 1.5) (51). First, a ubiquitin activating enzyme, E1, activates 
ubiquitin. Next, the ubiquitin is transferred from the ubiquitin-E1 complex to a ubiquitin-
conjugating enzyme, E2. Finally, E2 conjugates the ubiquitin to the targeted protein that is bound 
to an E3 ubiquitin ligase. The E3 ligases, along with other adaptor proteins, serve as the 
scaffolding to bring together the ubiquitin-E2 complex and the protein to be targeted for 
proteasomal degradation and allow for much of the specificity of the ubiquitin-proteasome 
pathway (52). Though most proteins are targeted to the proteasome through ubiquitin 
conjugation, there are a few ubiquitin-independent mechanisms (53). These include proteins that 
have ubiquitin-independent degron sequences, or chaperone proteins that cause proteasomal 
localization. 
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Figure 1.4 Lysosomal degradation. Proteins (blue) can be degraded by the lysosome through three methods: 
(1) Chaperone-mediated autophagy, where a chaperone protein (red, here Hsp as an example) guides another 
protein directly into the lysosome; (2) macroautophagy, where proteins are enclosed in an autophagosome 
that fuses to a lysosome, leading to protein degradation; or (3) microautophagy, where the lysosome itself 
invaginates to take in specific cytosolic proteins.
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2
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Figure 1.5 Ubiquitination of protein substrates. Proteins are conjugated to a ubiquitin (green) using three 
enzymes. First, E1 binds to ubiquitin. Next, ubiquitin is transferred to E2. Finally, the E2/ubiquitin complex 
binds to E3, which serves as the adaptor protein for the substrate to be degraded. The ubiquitin is then 
transferred to the substrate protein.
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Once a protein has been ubiquitinated (or localized to the proteasome by ubiquitin-
independent means), it is then degraded by the 26S proteasome (51, 52, 54). The proteasome is 
comprised of a 20S barrel-shaped core, with two 19S subunits on either end. Ubiquitinated 
proteins enter the proteasome through one of the 19S subunits, where the ubiquitin chain is 
cleaved off, broken down, and released into the cytoplasm. The protein then travels through the 
20S barrel, is degraded, and then small amino acid products exit through the other 19S subunit. 
This activity of the proteasome helps to mediate protein turnover and remove any improperly 
folded or damaged proteins within the cell. Additionally, the proteasome plays a role in 
immunity by generating antigenic peptides that can be presented on the outside of the cell so that 
the host can identify foreign peptides more readily (52, 55). 
 
Immune response to adenovirus infection 
 During viral infection, one trigger of the innate immune response is dsRNA fragments 
produced by the virus during replication (56, 57). The presence of dsRNA has been confirmed in 
cells infected with hAds, herpes simplex virus, and vaccinia virus using a dsRNA-specific 
antibody or other methods (58, 59). In DNA viruses, it has been proposed that dsRNA results 
from overlapping convergent transcription during infection.  
Activation of PKR is a major innate immune response to viral infection (Fig. 1.6). PKR is 
an interferon-induced protein that is comprised of two major domains, an N-terminal dsRNA 
binding domain and a C-terminal serine/threonine kinase domain (39, 60). When PKR binds to 
dsRNA (41-43), it becomes activated by dimerizing and transautophosphorylating on multiple 
resides, including residues S242, T255, T258, and T446 (61-66). When activated, PKR 
phosphorylates eIF2a, causing inhibition of protein synthesis and reduced viral replication  
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Figure 1.6 Translation arrest by PKR. PKR is activated by dsRNA, which is produced by viruses when they 
replicate. When PKR is activated, it phosphorylates translation factor eIF2α, which reduces translation and 
leads to reduced viral replication.
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PKR P
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(7, 32-34). This inhibition is not specific to viral mRNA, and leads to an overall global reduction 
in translation. However, there is an upregulation in transcription of specific stress response genes 
such as ATF-3, which can lead to apoptosis (67). 
 
Virus interactions with host protein PKR 
Many viruses encode gene products that block PKR activation or inhibit its ability to 
phosphorylate eIF2a (68). A common mechanism is to produce a viral protein that binds and 
sequesters dsRNA, blocking its interaction with PKR. Examples of this are vaccinia virus E3L 
(69-71), influenza virus NS1 (72, 73), and Ebola virus protein VP35 (74). Other viruses produce 
proteins or RNA that bind directly to PKR to inhibit its activation, such as herpes simplex virus 
US11 (75, 76), HIV-1 Tat protein (77, 78) or TAR RNA (79), and hAd virus-associated (VA) 
RNAs (7, 80-82).  
Degradation of PKR by viruses is a less documented method of regulating PKR. To date 
PKR degradation has been reported in six RNA viruses: Toscana virus (TOSV) (83), Rift Valley 
fever virus (RVFV) (84-86), poliovirus (87, 88), foot-and-mouth disease virus (FMDV) (89, 90), 
encephalomyocarditis virus (EMCV, strain mengovirus) (91, 92), and enterovirus A71 (93).  
RVFV and TOSV both degrade PKR via proteasomal mechanisms involving a viral 
nonstructural protein (NSs) (86, 94, 95). RVFV NSs recruits a SCF (SKP1-CUL1-F-box)FBXW11 
E3 ubiquitin ligase to ubiquitinate PKR and target it to the proteasome (Fig. 1.7) (86, 95). This 
degradation occurs in nuclear and cytoplasmic compartments, even though PKR mRNA levels 
are increased during infection, and degradation does not require PKR phosphorylation (85). 
However, even though an E3 ubiquitin ligase is recruited to PKR and PKR is degraded by the 
proteasome, ubiquitination could not be demonstrated (86). This is also true for another host  
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Figure 1.7 PKR degradation by Rift Valley fever virus (RVFV), adapted from Figure 5E from Mudhasani et 
al. As described in Mudhasani et al., 2016 and Kainulainen et al., 2016, NSs from RVFV binds to PKR and 
recruits the E3 ligase complex consisting of CUL1, SKP1, and FBXW11. This complex, in addition to an E2 
enzyme and the E2 adaptor Rbx, conjugates ubiquitin (green) to PKR, leading to its degradation.
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protein, p62, which is involved in transcriptional regulation, and which is degraded by a similar 
E3 ligase complex recruited by RVFV NSs (96). p62 degradation is a result of proteasome 
activity mediated by NSs, yet ubiquitination could not be demonstrated. The mechanism for PKR 
proteasomal degradation by NSs has not been described for TOSV (94). However, similar to 
RVFV, TOSV NSs interacts with PKR, and PKR phosphorylation is not required for degradation 
by TOSV NSs. 
In FMDV infection, although PKR mRNA levels are increased, phospho-PKR and PKR 
protein levels begin decreasing as soon as 12 hours post infection (hpi) in PK-15 cells (89, 90). 
Additionally, if the interferon stimulation pathway is interrupted, PKR protein levels start to 
decrease as soon as 6 hpi. FMDV uses the other major cellular protein degradation pathway, the 
lysosome, to degrade PKR during infection (90). Though the mechanism is unclear, expression 
of the major FMDV protease 3Cpro  is required for PKR degradation by the lysosome. However, 
3Cpro does not interact with PKR, nor is its protease activity required for PKR degradation.  
The enterovirus A71 protease 3Cpro causes PKR degradation by direct interaction, 
cleaving PKR at a site distinct from where PKR is cleaved during apoptosis (93). Interestingly, 
the kinase activity of PKR reduces enterovirus A71 replication, but a kinase-dead PKR increases 
viral protein accumulation. Viral 3Cpro cleaves PKR between the dsRNA-binding domain and the 
kinase domain, so the free dsRNA-binding domain then binds free dsRNA and prevents further 
activation of functional PKR molecules (Fig. 1.8). 
The mechanism of PKR depletion by poliovirus is unclear, though gene expression is 
required, and the major poliovirus proteases (2A and 3C) are not directly involved (87, 88). 
Overexpression of the 2A, 3C, or 3CD proteases in HeLa cells does not reduce PKR protein 
levels; however, the addition of EDTA, a protease inhibitor, or trypsin to poliovirus-infected  
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Figure 1.8 PKR degradation by enterovirus A71, adapted from Figure 8 from Chang et al. As described in 
Chang et al., 2017, 3Cpro (3C, blue) from enterovirus A71 binds to PKR and cleaves it at Q188-S189, 
between the dsRNA binding domain and the kinase domain. Once cleaved, the fragment with the kinase 
domain is degraded, and the fragment with the dsRNA binding domain binds to and sequesters dsRNA 
produced by the virus. Sequestering dsRNA reduces the activation of uncleaved PKR proteins, thus 
increasing viral replication.
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extracts prevents PKR depletion, suggesting a protease with a cation requirement is responsible 
for PKR degradation (87). Additionally, treatment of infected extracts with RNase A or RNase 
III also prevents PKR degradation, indicating that there is also an RNA component required for 
PKR depletion by poliovirus. Much like RVFV and TOSV, PKR phosphorylation is not required 
for PKR depletion. 
During EMCV infection in HeLa cells, PKR is depleted as early 2 hpi, and phospho-PKR 
is depleted by 4 hpi. When the HeLa cells were treated with interferon prior to infection, both 
phospho-PKR and PKR protein levels were elevated at 2 and 4 hpi. This is not surprising, 
because PKR is an interferon-stimulated gene (39, 60). However, even with the initial increase in 
PKR protein, both phospho-PKR and PKR protein levels begin to decrease by 6 hpi, indicating 
that the virus depletes PKR. It is likely that the depletion takes longer than in non-interferon-
stimulated cells because there is more PKR present in the cell to begin with. The mechanism by 
which EMCV depletes PKR during infection is unknown (91, 92). 
 
Virus interactions with host protein GCN2 
There is much research implicating PKR in the innate immune response to a wide range 
of viruses, and there are a variety of virus counter-responses. In contrast, GCN2, which becomes 
activated and phosphorylates eIF2a in response to amino acid deprivation, UV irradiation, and 
oxidative stress, is less well studied as a player in the innate immune response to viruses (Fig. 
1.9). Virus infections may be indirectly activating GCN2 by triggering changes in amino acid 
metabolism. 
For example, mouse cytomegalovirus (MCMV) infection leads to the production of 
25-hydroxycholesterol, reducing the levels of intracellular cysteine and/or generating oxidative  
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Figure 1.9 Translation arrest by GCN2. GCN2 is activated by amino acid deprivation, which causes an 
increase in uncharged tRNA binding to GCN2. When GCN2 is activated by phosphorylation, it 
phosphorylates translation factor eIF2α, which reduces translation.
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stress, thus activating GCN2 (97). 25-hydroxycholesterol triggers antiviral eIF2a 
phosphorylation, but only when GCN2 is present in the cells (97). Additionally, when GCN2-/- 
peritoneal macrophages and mice are infected with MCMV, they have significantly increased 
susceptibility compared to wild type macrophages and mice (98). Taken together, these results 
show that GCN2 is activated during MCMV during infection and plays an important antiviral 
role. 
Another virus that triggers GCN2 activation by depleting amino acids is the yellow fever 
virus vaccine (YF-17D) (99). After incubation with YF-17D, dendritic cells have significantly 
lower levels of free arginine and a subsequent increase in phosphorylated GCN2 and eIF2a. In 
GCN2-/- dendritic cells incubated with YF-17D, autophagy is reduced compared to wild type 
dendritic cells and there is reduction in the proliferation of CD8+ and CD4+ YF-17D-specific 
T-cells, suggesting that GCN2 plays a role in promoting antigen cross presentation and priming 
secondary immunity during YF-17D immunization.  
Another possible explanation for GCN2 playing an antiviral role during infection is when 
viruses directly activate GCN2. For example, Sindbis virus (SV) RNA binds and activates GCN2 
directly (100). Two specific regions in the SV RNA, GCN2-activating regions, bind directly to 
the HisRS-like domain of GCN2 as long as they are not denatured, suggesting that the secondary 
structures of these regions may mimic uncharged tRNAs. In the presence of SV RNA, GCN2 
and eIF2a phosphorylation are increased, leading to a reduction in SV RNA replication. 
Additionally, overexpression of GCN2 in SV-infected cells reduces virus yield, assayed by 
plaque assays. These data show that GCN2 plays an antiviral role during SV infection by 
inhibiting SV RNA replication through eIF2a phosphorylation after being activated by SV RNA.   
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The prunnus necrotic ringspot virus (PNRSV), a plant virus, produces a movement 
protein, MP, that enlarges the plasmodesmata pores to allow for cell-to-cell movement of the 
virus. MP increases eIF2a phosphorylation when it is expressed in yeast (101). Since GCN2 is 
the only eIF2a kinase in yeast, this suggests that MP may activate GCN2 during PNRSV 
infection of plants. However, the mechanism for this activation is unknown.  
Data suggest that GCN2 plays an antiviral role during vesicular stomatitis virus (VSV) 
infection, but the mechanism is unknown. VSV has increased viral replication and viral protein 
accumulation in GCN2-/- mouse embryonic fibroblasts (MEFs) compared to wild type MEFs 
(102, 103). Additionally, when a mutant of GCN2 containing only the eIF2a kinase domain is 
transfected into VSV-infected cells and becomes activated, viral protein accumulation is reduced 
compared to cells in which this mutant protein is present but inactive (103). When MEFs 
expressing a non-phosphorylatable form of eIF2a are infected with VSV, there is no difference 
in viral protein accumulation compared to wild type MEFs (103). This suggests that GCN2 
activation combats VSV infection in an eIF2a-independent manner, implying that there are 
antiviral downstream targets for activated GCN2 other than eIF2a during infection. 
While MCMV, YF-17D, SV, and PNRSV activate GCN2 directly or indirectly, some 
viruses have also evolved methods for inactivating or inhibiting GCN2 activity, either by direct 
interaction with GCN2 or by affecting an upstream or downstream effector of GCN2. Herpes 
simplex virus 1 (HSV-1) indirectly inhibits GCN2 by targeting GCN1, an upstream activator of 
GCN2 (104, 105). HSV-1 glycoprotein H (gH) directly interacts with GCN1, changing its 
localization from the cytoplasm to the nuclear rim, and overexpression of gH reduces eIF2a 
phosphorylation compared to cells with no gH (104). Taken together, these results suggest that 
HSV-1 reduces eIF2a phosphorylation by sequestering GCN1 and keeping it from activating 
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GCN2 during infection. Severe acute respiratory syndrome-related coronavirus also indirectly 
inhibits GCN2 by causing a depletion of GCN2 protein from the cell late in infection, likely 
causing this reduction by decreasing host gene transcription overall (106). 
The K3L protein from vaccinia virus also inactivates GCN2 (107). K3L binds to the 
kinase domain of GCN2, and this binding does not require the GCN2 kinase activity. When K3L 
is expressed in yeast, it reduces GCN2 and eIF2a phosphorylation, even under starvation 
conditions, when GCN2 would normally be activated and eIF2a should have increased 
phosphorylation. 
Like SV RNA, HIV-1 RNA also triggers GCN2 activation directly by binding to the 
HisRS-like domain of GCN2, causing an increase in eIF2a phosphorylation (Fig. 1.10) (108). 
However, HIV-1 encodes two different proteins that interact with GCN2. The first is HIV-1pro, a 
protease that cleaves human and mouse GCN2 after amino acid 560/559 (108). Once GCN2 is 
cleaved by HIV-1pro, it loses nearly all of its capability to phosphorylate eIF2a. The second viral 
protein employed by HIV-1 to inhibit GCN2 activity is integrase (IN) (109, 110). HIV-1 IN is 
involved in HIV-1 genome integration into the host DNA during infection (110). While IN does 
not activate GCN2, it binds directly to the kinase domain of GCN2 in the same region that eIF2a 
and K3L bind. This suggests that IN may act as a substrate for GCN2 and reduce its activity, 
because translation is higher in the presence of IN (109, 110). However, GCN2 phosphorylates 
HIV-1 IN, leading to reduced IN enzymatic activity and fewer integration events during infection 
(110).  
Interestingly, HIV-1 also has mechanisms that use GCN2 activation to its advantage. 
When the GCN2/eIF2a phosphorylation pathway is activated and global translation is decreased, 
expression of some host genes involved in amino acid biosynthesis is upregulated, including  
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Figure 1.10 HIV-1 interactions with GCN2, adapted from Figure 7F from Jiang et al. As described in Jiang 
et al., 2017 and del Pino et al., 2012, HIV-1 activates GCN2 by producing RNA that binds to the HisRS
domain of GCN2 and by reducing free amino acid levels. GCN2 activation leads to eIF2α phosphorylation, 
which reduces translation but stimulates the transcription of ATF4. ATF4 binds to the LTR of HIV-1 and 
causes reactivation of latent HIV-1, leading to increased viral replication. HIV-1 produces a protease that 
cleaves GCN2, and thus viral protein translation can occur. HIV-1 integrase also binds to GCN2 and acts as 
a psuedosubstrate for GCN2, though it is unclear if that reduces eIF2! phosphorylation.
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ATF4 (111). ATF4 mRNA binds to the HIV-1 LTR and enhances HIV-1 transcription and 
replication (112). Taken together, these data suggest that not only can HIV-1 use GCN2 
activation to its advantage, but it can also impair GCN2 activity to maintain protein translation in 
HIV-1-infected cells. 
 
Conclusion 
In the next two chapters, I will discuss the role of PKR and GCN2 during MAV-1 
infection. PKR-/- mice, macrophages, and MEFs were more susceptible to MAV-1 infection 
compared to wild type mice and cells. PKR mRNA transcription was significantly increased by 
72 hpi in infected macrophages compared mock infected macrophages, but PKR protein levels at 
that time point were significantly reduced in infected macrophages. PKR protein was also almost 
completely depleted by 24 hpi in C57BL/6 MEFs and CMT93 cells. Treating cells with 
proteasome inhibitors prevented PKR depletion, indicating that MAV-1 infection causes PKR to 
be degraded by the proteasome. PKR was only degraded when early viral genes were expressed 
during infection, indicating that an early viral gene is responsible for mediating PKR 
degradation. Degradation of PKR has not previously been reported for a DNA virus. GCN2-/- 
(atchoum) mice and macrophages were more susceptible to MAV-1 infection compared with 
wild type animals, though there was no difference in viral yield between organs from wild type 
and atchoum mice. 
 
Bibliography 
 
1. Harrach B, Benko M, Both GW, Brown M, Davison AJ, Echavarria M, Hess M, Jones 
MS, Kajon A, Lehmkuhl HD, Mautner V, Mittal SK, Wadell G. 2011. Virus Taxonomy: 
Ninth report of the international committee on taxonomy of viruses, p 128. In King 
AMQ, Adams MJ, Carstens EB, Lefkowitz EJ (ed). Elsevier. 
	 23 
2. Ghebremedhin B. 2014. Human adenovirus: Viral pathogen with increasing importance. 
Eur J Micro Immunol 4:26-33. 
3. Guida JD, Fejer G, Pirofski LA, Brosnan CF, Horwitz MS. 1995. Mouse adenovirus type 
1 causes a fatal hemorrhagic encephalomyelitis in adult C57BL/6 but not BALB/c mice. J 
Virol 69:7674-81. 
4. Spindler KR, Fang L, Moore ML, Hirsch GN, Brown CC, Kajon A. 2001. SJL/J mice are 
highly susceptible to infection by mouse adenovirus type 1. J Virol 75:12039-46. 
5. Kring SC, King CS, Spindler KR. 1995. Susceptibility and signs associated with mouse 
adenovirus type 1 infection of adult outbred Swiss mice. J Virol 69:8084-8. 
6. Smith K, Brown CC, Spindler KR. 1998. The role of mouse adenovirus type 1 early 
region 1A in acute and persistent infections in mice. J Virol 72:5699-706. 
7. Berk AJ. 2013. Adenoviridae: The viruses and their replication. In Knipe DM, Howley P 
(ed), Fields Virology, 6th ed, vol 2. Lippincott Williams & Wilkins, Philadelphia. 
8. Zhang Y, Huang W, Ornelles DA, Gooding LR. 2010. Modeling adenovirus latency in 
human lymphocyte cell lines. J Virol 84:8799-810. 
9. Ashley SL, Pretto CD, Stier MT, Kadiyala P, Castro-Jorge L, Hsu TH, Doherty R, 
Carnahan KE, Castro MG, Lowenstein PR, Spindler KR. 2017. Matrix Metalloproteinase 
Activity in Infections by an Encephalitic Virus, Mouse Adenovirus Type 1. J Virol 91. 
10. Gralinski LE, Ashley SL, Dixon SD, Spindler KR. 2009. Mouse adenovirus type 1-
induced breakdown of the blood-brain barrier. J Virol 83:9398-410. 
11. Michael BD, Griffiths MJ, Granerod J, Brown D, Davies NW, Borrow R, Solomon T. 
2016. Characteristic Cytokine and Chemokine Profiles in Encephalitis of Infectious, 
Immune-Mediated, and Unknown Aetiology. PLoS One 11:e0146288. 
12. Castro-Jorge LA, Pretto CD, Smith AB, Foreman O, Carnahan KE, Spindler KR. 2017. A 
Protective Role for Interleukin-1 Signaling during Mouse Adenovirus Type 1-Induced 
Encephalitis. J Virol 91. 
13. Moore ML, McKissic EL, Brown CC, Wilkinson JE, Spindler KR. 2004. Fatal 
disseminated mouse adenovirus type 1 infection in mice lacking B cells or Bruton's 
tyrosine kinase. J Virol 78:5584-90. 
14. Moore ML, Brown CC, Spindler KR. 2003. T cells cause acute immunopathology and 
are required for long-term survival in mouse adenovirus type 1-induced 
encephalomyelitis. J Virol 77:10060-70. 
15. Charles PC, Guida JD, Brosnan CF, Horwitz MS. 1998. Mouse adenovirus type-1 
replication is restricted to vascular endothelium in the CNS of susceptible strains of mice. 
Virology 245:216-28. 
	 24 
16. Pirofski L, Horwitz MS, Scharff MD, Factor SM. 1991. Murine adenovirus infection of 
SCID mice induces hepatic lesions that resemble human Reye syndrome. Proc Natl Acad 
Sci U S A 88:4358-62. 
17. Ginsberg HS. 1999. The life and times of adenoviruses. Adv Virus Res 54:1-13. 
18. Philipson L, Lonberg-Holm K, Pettersson U. 1968. Virus-receptor interaction in an 
adenovirus system. J Virol 2:1064-75. 
19. Greber UF, Willetts M, Webster P, Helenius A. 1993. Stepwise dismantling of 
adenovirus 2 during entry into cells. Cell 75:477-86. 
20. Ginsberg HS. 1958. Characteristics on the adenoviruses. III. Reproductive cycle of types 
1 to 4. J Exp Med 107:133-52. 
21. Velicer LF, Ginsberg HS. 1970. Synthesis, transport, and morphogenesis of type 
adenovirus capsid proteins. J Virol 5:338-52. 
22. Thomas GP, Mathews MB. 1980. DNA replication and the early to late transition in 
adenovirus infection. Cell 22:523-33. 
23. Berk AJ, Sharp PA. 1977. Sizing and mapping of early adenovirus mRNAs by gel 
electrophoresis of S1 endonuclease-digested hybrids. Cell 12:721-32. 
24. Berget SM, Sharp PA. 1979. Structure of late adenovirus 2 heterogeneous nuclear RNA. 
J Mol Biol 129:547-65. 
25. Larsson S, Svensson C, Akusjarvi G. 1992. Control of adenovirus major late gene 
expression at multiple levels. J Mol Biol 225:287-98. 
26. Meissner JD, Hirsch GN, LaRue EA, Fulcher RA, Spindler KR. 1997. Completion of the 
DNA sequence of mouse adenovirus type 1: sequence of E2B, L1, and L2 (18-51 map 
units). Virus Res 51:53-64. 
27. Young CS. 2003. The structure and function of the adenovirus major late promoter. Curr 
Top Microbiol Immunol 272:213-49. 
28. Song B, Hu SL, Darai G, Spindler KR, Young CS. 1996. Conservation of DNA sequence 
in the predicted major late promoter regions of selected mastadenoviruses. Virology 
220:390-401. 
29. Logan J, Shenk T. 1984. Adenovirus tripartite leader sequence enhances translation of 
mRNAs late after infection. Proc Natl Acad Sci U S A 81:3655-9. 
30. Berkner KL, Sharp PA. 1985. Effect of the tripartite leader on synthesis of a non-viral 
protein in an adenovirus 5 recombinant. Nucleic Acids Res 13:841-57. 
	 25 
31. Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. 2016. The 
integrated stress response. EMBO Rep 17:1374-1395. 
32. Wek RC. 2018. Role of eIF2alpha kinases in translational control and adaptation to 
cellular stress. Cold Spring Harb Perspect Biol 10. 
33. Farrell PJ, Balkow K, Hunt T, Jackson RJ, Trachsel H. 1977. Phosphorylation of 
initiation factor elF-2 and the control of reticulocyte protein synthesis. Cell 11:187-200. 
34. Tahara SM, Traugh JA, Sharp SB, Lundak TS, Safer B, Merrick WC. 1978. Effect of 
hemin on site-specific phosphorylation of eukaryotic initiation factor 2. Proc Natl Acad 
Sci USA 75:789-93. 
35. Harding HP, Zhang Y, Ron D. 1999. Protein translation and folding are coupled by an 
endoplasmic-reticulum-resident kinase. Nature 397:271-4. 
36. Berlanga JJ, Herrero S, de Haro C. 1998. Characterization of the hemin-sensitive 
eukaryotic initiation factor 2alpha kinase from mouse nonerythroid cells. J Biol Chem 
273:32340-6. 
37. Chen JJ, Throop MS, Gehrke L, Kuo I, Pal JK, Brodsky M, London IM. 1991. Cloning of 
the cDNA of the heme-regulated eukaryotic initiation factor 2 alpha (eIF-2 alpha) kinase 
of rabbit reticulocytes: homology to yeast GCN2 protein kinase and human double-
stranded-RNA-dependent eIF-2 alpha kinase. Proc Natl Acad Sci U S A 88:7729-33. 
38. Shi Y, Vattem KM, Sood R, An J, Liang J, Stramm L, Wek RC. 1998. Identification and 
characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase, PEK, 
involved in translational control. Mol Cell Biol 18:7499-509. 
39. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, Hovanessian AG. 
1990. Molecular cloning and characterization of the human double-stranded RNA-
activated protein kinase induced by interferon. Cell 62:379-90. 
40. Ramirez M, Wek RC, Hinnebusch AG. 1991. Ribosome association of GCN2 protein 
kinase, a translational activator of the GCN4 gene of Saccharomyces cerevisiae. Mol Cell 
Biol 11:3027-36. 
41. Feng GS, Chong K, Kumar A, Williams BR. 1992. Identification of double-stranded 
RNA-binding domains in the interferon-induced double-stranded RNA-activated p68 
kinase. Proc Natl Acad Sci USA 89:5447-51. 
42. Kuhen KL, Samuel CE. 1997. Isolation of the interferon-inducible RNA-dependent 
protein kinase Pkr promoter and identification of a novel DNA element within the 5'-
flanking region of human and mouse Pkr genes. Virology 227:119-30. 
43. Patel RC, Sen GC. 1992. Identification of the double-stranded RNA-binding domain of 
the human interferon-inducible protein kinase. J Biol Chem 267:7671-6. 
	 26 
44. Ranu RS. 1979. Regulation of protein synthesis in rabbit reticulocyte lysates: the 
hemeregulated protein kinase (HRI) and double stranded RNA induced protein kinase 
(dRI) phosphorylate the same site(s) on initiation factor eIF-2. Biochem Biophys Res 
Commun 91:1437-44. 
45. Wek RC, Ramirez M, Jackson BM, Hinnebusch AG. 1990. Identification of positive-
acting domains in GCN2 protein kinase required for translational activation of GCN4 
expression. Mol Cell Biol 10:2820-31. 
46. Grallert B, Boye E. 2013. GCN2, an old dog with new tricks. Biochem Soc Trans 
41:1687-91. 
47. Schulz O, Pichlmair A, Rehwinkel J, Rogers NC, Scheuner D, Kato H, Takeuchi O, 
Akira S, Kaufman RJ, Reis e Sousa C. 2010. Protein kinase R contributes to immunity 
against specific viruses by regulating interferon mRNA integrity. Cell Host Microbe 
7:354-61. 
48. Cooper GM. 2000. Protein Degradation, The Cell: A Molecular Approach, 2nd ed. 
Sinauer Associates, Sunderland, MA. 
49. Klionsky DJ. 2005. The molecular machinery of autophagy: unanswered questions. J Cell 
Sci 118:7-18. 
50. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D, Goldberg AL. 
1994. Inhibitors of the proteasome block the degradation of most cell proteins and the 
generation of peptides presented on MHC class I molecules. Cell 78:761-71. 
51. Glickman MH, Ciechanover A. 2002. The ubiquitin-proteasome proteolytic pathway: 
destruction for the sake of construction. Physiol Rev 82:373-428. 
52. Lecker SH, Goldberg AL, Mitch WE. 2006. Protein degradation by the ubiquitin-
proteasome pathway in normal and disease states. J Am Soc Nephrol 17:1807-19. 
53. Erales J, Coffino P. 2014. Ubiquitin-independent proteasomal degradation. Biochim 
Biophys Acta 1843:216-21. 
54. Voges D, Zwickl P, Baumeister W. 1999. The 26S proteasome: a molecular machine 
designed for controlled proteolysis. Annu Rev Biochem 68:1015-68. 
55. Shastri N, Schwab S, Serwold T. 2002. Producing nature's gene-chips: the generation of 
peptides for display by MHC class I molecules. Annu Rev Immunol 20:463-93. 
56. Marcus PI, Sekellick MJ. 1977. Defective interfering particles with covalently linked [+/-
]RNA induce interferon. Nature 266:815-9. 
57. Jacobs BL, Langland JO. 1996. When two strands are better than one: the mediators and 
modulators of the cellular responses to double-stranded RNA. Virology 219:339-49. 
	 27 
58. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded 
RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable 
amounts by negative-strand RNA viruses. J Virol 80:5059-64. 
59. Duesberg PH, Colby C. 1969. On the biosynthesis and structure of double-stranded RNA 
in vaccinia virus-infected cells. Proc Natl Acad Sci U S A 64:396-403. 
60. McCormack SJ, Thomis DC, Samuel CE. 1992. Mechanism of interferon action: 
identification of a RNA binding domain within the N-terminal region of the human RNA-
dependent P1/eIF-2 alpha protein kinase. Virology 188:47-56. 
61. Dey M, Mann BR, Anshu A, Mannan MA. 2014. Activation of protein kinase PKR 
requires dimerization-induced cis-phosphorylation within the activation loop. J Biol 
Chem 289:5747-57. 
62. Taylor DR, Lee SB, Romano PR, Marshak DR, Hinnebusch AG, Esteban M, Mathews 
MB. 1996. Autophosphorylation sites participate in the activation of the double-stranded-
RNA-activated protein kinase PKR. Mol Cell Biol 16:6295-302. 
63. Dabo S, Meurs EF. 2012. dsRNA-dependent protein kinase PKR and its role in stress, 
signaling and HCV infection. Viruses 4:2598-635. 
64. Mundschau LJ, Faller DV. 1994. Endogenous inhibitors of the dsRNA-dependent eIF-2 
alpha protein kinase PKR in normal and ras-transformed cells. Biochimie 76:792-800. 
65. Hovanessian AG, Galabru J. 1987. The double-stranded RNA-dependent protein kinase 
is also activated by heparin. Eur J Biochem 167:467-73. 
66. Galabru J, Hovanessian A. 1987. Autophosphorylation of the protein kinase dependent on 
double-stranded RNA. J Biol Chem 262:15538-44. 
67. Guerra S, Lopez-Fernandez LA, Garcia MA, Zaballos A, Esteban M. 2006. Human gene 
profiling in response to the active protein kinase, interferon-induced serine/threonine 
protein kinase (PKR), in infected cells. Involvement of the transcription factor ATF-3 IN 
PKR-induced apoptosis. J Biol Chem 281:18734-45. 
68. Dzananovic E, McKenna SA, Patel TR. 2018. Viral proteins targeting host protein kinase 
R to evade an innate immune response: A mini review. Biotechnol Genet Eng Rev 34:33-
59. 
69. Chang HW, Jacobs BL. 1993. Identification of a conserved motif that is necessary for 
binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 
194:537-47. 
70. Rice AD, Turner PC, Embury JE, Moldawer LL, Baker HV, Moyer RW. 2011. Roles of 
vaccinia virus genes E3L and K3L and host genes PKR and RNase L during intratracheal 
infection of C57BL/6 mice. J Virol 85:550-67. 
	 28 
71. Carroll K, Elroy-Stein O, Moss B, Jagus R. 1993. Recombinant vaccinia virus K3L gene 
product prevents activation of double-stranded RNA-dependent, initiation factor 2 alpha-
specific protein kinase. J Biol Chem 268:12837-42. 
72. Lu Y, Wambach M, Katze MG, Krug RM. 1995. Binding of the influenza virus NS1 
protein to double-stranded RNA inhibits the activation of the protein kinase that 
phosphorylates the elF-2 translation initiation factor. Virology 214:222-8. 
73. Tan SL, Katze MG. 1998. Biochemical and genetic evidence for complex formation 
between the influenza A virus NS1 protein and the interferon-induced PKR protein 
kinase. J Interferon Cytokine Res 18:757-66. 
74. Cardenas WB, Loo YM, Gale M, Jr., Hartman AL, Kimberlin CR, Martinez-Sobrido L, 
Saphire EO, Basler CF. 2006. Ebola virus VP35 protein binds double-stranded RNA and 
inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol 80:5168-78. 
75. Poppers J, Mulvey M, Khoo D, Mohr I. 2000. Inhibition of PKR activation by the 
proline-rich RNA binding domain of the herpes simplex virus type 1 Us11 protein. J 
Virol 74:11215-21. 
76. Cassady KA, Gross M, Roizman B. 1998. The herpes simplex virus US11 protein 
effectively compensates for the gamma1(34.5) gene if present before activation of protein 
kinase R by precluding its phosphorylation and that of the alpha subunit of eukaryotic 
translation initiation factor 2. J Virol 72:8620-6. 
77. Cai R, Carpick B, Chun RF, Jeang KT, Williams BR. 2000. HIV-I TAT inhibits PKR 
activity by both RNA-dependent and RNA-independent mechanisms. Arch Biochem 
Biophys 373:361-7. 
78. McMillan NA, Chun RF, Siderovski DP, Galabru J, Toone WM, Samuel CE, Mak TW, 
Hovanessian AG, Jeang KT, Williams BR. 1995. HIV-1 Tat directly interacts with the 
interferon-induced, double-stranded RNA-dependent kinase, PKR. Virology 213:413-24. 
79. Park H, Davies MV, Langland JO, Chang HW, Nam YS, Tartaglia J, Paoletti E, Jacobs 
BL, Kaufman RJ, Venkatesan S. 1994. TAR RNA-binding protein is an inhibitor of the 
interferon-induced protein kinase PKR. Proc Natl Acad Sci USA 91:4713-7. 
80. Thimmappaya B, Weinberger C, Schneider RJ, Shenk T. 1982. Adenovirus VAI RNA is 
required for efficient translation of viral mRNAs at late times after infection. Cell 31:543-
51. 
81. Mathews MB, Grodzicker T. 1981. Virus-associated RNAs of naturally occurring strains 
and variants of group C adenoviruses. J Virol 38:849-62. 
82. Reich PR, Forget BG, Weissman SM. 1966. RNA of low molecular weight in KB cells 
infected with adenovirus type 2. J Mol Biol 17:428-39. 
	 29 
83. Kalveram B, Ikegami T. 2013. Toscana virus NSs protein promotes degradation of 
double-stranded RNA-dependent protein kinase. J Virol 87:3710-8. 
84. Habjan M, Pichlmair A, Elliott RM, Overby AK, Glatter T, Gstaiger M, Superti-Furga G, 
Unger H, Weber F. 2009. NSs protein of Rift Valley fever virus induces the specific 
degradation of the double-stranded RNA-dependent protein kinase. J Virol 83:4365-75. 
85. Ikegami T, Narayanan K, Won S, Kamitani W, Peters CJ, Makino S. 2009. Rift Valley 
fever virus NSs protein promotes post-transcriptional downregulation of protein kinase 
PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 5:e1000287. 
86. Mudhasani R, Tran JP, Retterer C, Kota KP, Whitehouse CA, Bavari S. 2016. Protein 
kinase R degradation Is essential for Rift Valley fever virus infection and is regulated by 
SKP1-CUL1-F-box (SCF)FBXW11-NSs E3 ligase. PLoS Pathog 12:e1005437. 
87. Black TL, Barber GN, Katze MG. 1993. Degradation of the interferon-induced 68,000-
M(r) protein kinase by poliovirus requires RNA. J Virol 67:791-800. 
88. Black TL, Safer B, Hovanessian A, Katze MG. 1989. The cellular 68,000-Mr protein 
kinase is highly autophosphorylated and activated yet significantly degraded during 
poliovirus infection: Implications for translational regulation. J Virol 63:2244-51. 
89. Li W, Zhu Z, Cao W, Yang F, Zhang X, Li D, Zhang K, Li P, Mao R, Liu X, Zheng H. 
2016. Esterase D enhances type I interferon signal transduction to suppress foot-and-
mouth disease virus replication. Mol Immunol 75:112-21. 
90. Li C, Zhu Z, Du X, Cao W, Yang F, Zhang X, Feng H, Li D, Zhang K, Liu X, Zheng H. 
2017. Foot-and-mouth disease virus induces lysosomal degradation of host protein kinase 
PKR by 3C proteinase to facilitate virus replication. Virology 509:222-231. 
91. Rabouw HH, Langereis MA, Knaap RC, Dalebout TJ, Canton J, Sola I, Enjuanes L, 
Bredenbeek PJ, Kikkert M, de Groot RJ, van Kuppeveld FJ. 2016. Middle East 
respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress 
responses. PLoS Pathog 12:e1005982. 
92. Hovanessian AG, Galabru J, Meurs E, Buffet-Janvresse C, Svab J, Robert N. 1987. Rapid 
decrease in the levels of the double-stranded RNA-dependent protein kinase during virus 
infections. Virology 159:126-36. 
93. Chang YH, Lau KS, Kuo RL, Horng JT. 2017. dsRNA binding domain of PKR is 
proteolytically released by enterovirus A71 to facilitate viral replication. Front Cell Infect 
Microbiol 7:284. 
94. Kalveram B, Ikegami T. 2013. Toscana virus NSs protein promotes degradation of 
double-stranded RNA-dependent protein kinase. J Virol 87:3710-8. 
	 30 
95. Kainulainen M, Lau S, Samuel CE, Hornung V, Weber F. 2016. NSs virulence factor of 
Rift Valley fever virus engages the F-box proteins FBXW11 and beta-TRCP1 to degrade 
the antiviral protein kinase PKR. J Virol 90:6140-7. 
96. Ly HJ, Ikegami T. 2016. Rift Valley fever virus NSs protein functions and the similarity 
to other bunyavirus NSs proteins. Virol J 13:118. 
97. Shibata N, Carlin AF, Spann NJ, Saijo K, Morello CS, McDonald JG, Romanoski CE, 
Maurya MR, Kaikkonen MU, Lam MT, Crotti A, Reichart D, Fox JN, Quehenberger O, 
Raetz CR, Sullards MC, Murphy RC, Merrill AH, Jr., Brown HA, Dennis EA, Fahy E, 
Subramaniam S, Cavener DR, Spector DH, Russell DW, Glass CK. 2013. 25-
Hydroxycholesterol activates the integrated stress response to reprogram transcription 
and translation in macrophages. J Biol Chem 288:35812-23. 
98. Won S, Eidenschenk C, Arnold CN, Siggs OM, Sun L, Brandl K, Mullen TM, Nemerow 
GR, Moresco EM, Beutler B. 2012. Increased susceptibility to DNA virus infection in 
mice with a GCN2 mutation. J Virol 86:1802-8. 
99. Ravindran R, Khan N, Nakaya HI, Li S, Loebbermann J, Maddur MS, Park Y, Jones DP, 
Chappert P, Davoust J, Weiss DS, Virgin HW, Ron D, Pulendran B. 2014. Vaccine 
activation of the nutrient sensor GCN2 in dendritic cells enhances antigen presentation. 
Science 343:313-317. 
100. Berlanga JJ, Ventoso I, Harding HP, Deng J, Ron D, Sonenberg N, Carrasco L, de Haro 
C. 2006. Antiviral effect of the mammalian translation initiation factor 2alpha kinase 
GCN2 against RNA viruses. EMBO J 25:1730-1740. 
101. Aparicio F, Aparicio-Sanchis R, Gadea J, Sanchez-Navarro JA, Pallas V, Murguia JR. 
2011. A plant virus movement protein regulates the Gcn2p kinase in budding yeast. PLoS 
One 6:e27409. 
102. Berlanga JJ, Ventoso I, Harding HP, Deng J, Ron D, Sonenberg N, Carrasco L, de Haro 
C. 2006. Antiviral effect of the mammalian translation initiation factor 2alpha kinase 
GCN2 against RNA viruses. EMBO J 25:1730-40. 
103. Krishnamoorthy J, Mounir Z, Raven JF, Koromilas AE. 2008. The eIF2alpha kinases 
inhibit vesicular stomatitis virus replication independently of eIF2alpha phosphorylation. 
Cell Cycle 7:2346-51. 
104. Hirohata Y, Kato A, Oyama M, Kozuka-Hata H, Koyanagi N, Arii J, Kawaguchi Y. 
2015. Interactome analysis of herpes simplex virus 1 envelope glycoprotein H. Microbiol 
Immunol 59:331-7. 
105. Vazquez de Aldana CR, Marton MJ, Hinnebusch AG. 1995. GCN20, a novel ATP 
binding cassette protein, and GCN1 reside in a complex that mediates activation of the 
eIF-2 alpha kinase GCN2 in amino acid-starved cells. EMBO J 14:3184-99. 
	 31 
106. Krahling V, Stein DA, Spiegel M, Weber F, Muhlberger E. 2009. Severe acute 
respiratory syndrome coronavirus triggers apoptosis via protein kinase R but is resistant 
to its antiviral activity. J Virol 83:2298-309. 
107. Qian W, Zhu S, Sobolev AY, Wek RC. 1996. Expression of vaccinia virus K3L protein 
in yeast inhibits eukaryotic initiation factor-2 kinase GCN2 and the general amino acid 
control pathway. J Biol Chem 271:13202-7. 
108. del Pino J, Jimenez JL, Ventoso I, Castello A, Munoz-Fernandez MA, de Haro C, 
Berlanga JJ. 2012. GCN2 has inhibitory effect on human immunodeficiency virus-1 
protein synthesis and is cleaved upon viral infection. PLoS One 7:e47272. 
109. Cosnefroy O, Jaspart A, Calmels C, Parissi V, Fleury H, Ventura M, Reigadas S, 
Andreola ML. 2013. Activation of GCN2 upon HIV-1 infection and inhibition of 
translation. Cell Mol Life Sci 70:2411-21. 
110. Jaspart A, Calmels C, Cosnefroy O, Bellecave P, Pinson P, Claverol S, Guyonnet-
Duperat V, Dartigues B, Benleulmi MS, Mauro E, Gretteau PA, Parissi V, Metifiot M, 
Andreola ML. 2017. GCN2 phosphorylates HIV-1 integrase and decreases HIV-1 
replication by limiting viral integration. Sci Rep 7:2283. 
111. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. 2000. Regulated 
translation initiation controls stress-induced gene expression in mammalian cells. Mol 
Cell 6:1099-108. 
112. Jiang G, Santos Rocha C, Hirao LA, Mendes EA, Tang Y, Thompson GR, 3rd, Wong JK, 
Dandekar S. 2017. HIV Exploits antiviral host innate GCN2-ATF4 signaling for 
establishing viral replication early in infection. MBio 8. 
 
	 32 
 
 
 
Chapter II  
Enhanced replication of mouse adenovirus type 1 following virus-induced degradation of 
protein kinase R (PKR) 
 
Modified from: 
Goodman DE, Pretto CD, Krepostman TA, Carnahan KE, and Spindler KR. “Enhanced 
replication of mouse adenovirus type 1 following virus-induced degradation of protein kinase R 
(PKR).” In press, mBio, March 2019. 
 
Abstract 
Protein kinase R (PKR) plays a major role in activating host immunity during infection 
by sensing double-stranded (ds) RNA produced by viruses. Once activated by dsRNA, PKR 
phosphorylates the translation factor eIF2a, halting cellular translation. Many viruses have 
methods of inhibiting PKR activation or its downstream effects, circumventing protein synthesis 
shutdown. These include sequestering dsRNA or producing proteins that bind to and inhibit PKR 
activation. Here we describe our finding that in multiple cell types, PKR was depleted during 
mouse adenovirus type 1 (MAV-1) infection. MAV-1 did not appear to be targeting PKR at a 
transcriptional or translational level because total PKR mRNA levels and levels of PKR mRNA 
bound to polysomes were unchanged or increased during MAV-1 infection. However, inhibiting 
the proteasome reduced the PKR depletion seen in MAV-1-infected cells, whereas inhibiting the 
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lysosome had no effect. This suggests that proteasomal degradation alone is responsible for PKR 
degradation during MAV-1 infection. Time course experiments indicate that the degradation 
occurs early after infection. Infecting cells with UV-inactivated virus prevented PKR 
degradation, whereas inhibiting viral DNA replication did not. Together these results suggest that 
an early viral gene is responsible. Degradation of PKR is a rare mechanism to oppose PKR 
activity, and it has only been described in only six RNA viruses. To our knowledge, this is the 
first example of a DNA virus counteracting PKR by degrading it. 
 
Importance 
The first line of defense in cells during viral infection is the innate immune system, which 
is activated by different viral products. PKR is a part of this innate immune system and is 
induced by interferon (IFN) and activated by dsRNA produced by DNA and RNA viruses. PKR 
is such an important part of the antiviral response that many viral families have gene products to 
counteract its activation or the resulting effects of its activity. Although a few RNA viruses 
degrade PKR, this method of counteracting PKR has not been reported for any DNA viruses. 
MAV-1 does not encode virus-associated (VA) RNAs, a human adenoviral defense against PKR 
activation. Instead, MAV-1 degrades PKR, and it is the first DNA virus reported to do so. The 
innate immune evasion by PKR degradation is a previously unidentified way for a DNA virus to 
circumvent the host antiviral response. 
 
Introduction 
Activation of PKR is a major innate immune response to viral infection. PKR is an IFN-
induced protein that is comprised of two major domains, an N-terminal dsRNA binding domain 
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and a C-terminal serine/threonine kinase domain (1, 2). PKR binds to dsRNA (3-5) and once 
bound, it becomes activated by dimerizing and autophosphorylating (6-9). When activated, PKR 
phosphorylates eukaryotic translation initiation factor 2a (eIF2a), causing inhibition of protein 
synthesis and reduced viral replication (10-13). Many viruses encode gene products that block 
PKR activation or inhibit its ability to phosphorylate eIF2a (14). A common mechanism is to 
produce a viral protein that binds and sequesters dsRNA, blocking its interaction with PKR. 
Examples of this are vaccinia virus E3L (15-17), influenza virus NS1 (18, 19), and Ebola virus 
protein VP35 (20). Other viruses produce proteins or RNA that bind directly to PKR to inhibit its 
activation, such as herpes simplex virus US11 (21, 22), HIV-1 Tat protein (23, 24) or TAR RNA 
(25), and human adenovirus (hAd) VA RNAs (10, 26-28).  
Degradation of PKR by viruses is a less documented method of regulating PKR. To date 
PKR degradation has been reported in six RNA viruses: Toscana virus (TOSV) (29), Rift Valley 
fever virus (RVFV) (30-32), poliovirus (33, 34), foot-and-mouth disease virus (FMDV) (35, 36), 
encephalomyocarditis virus (EMCV, strain mengovirus) (37, 38), and enterovirus 71 (39). RVFV 
and TOSV both degrade PKR via proteasomal mechanisms involving a viral nonstructural 
protein (NSs) (32, 40, 41). RVFV NSs recruits a SCF (SKP1-CUL1-F-box)FBXW11 E3 ubiquitin 
ligase to ubiquitinate PKR and target it to the proteasome, though PKR ubiquitination could not 
be demonstrated (32, 41). The mechanism for PKR proteasomal degradation by NSs has not been 
described for TOSV (40). FMDV uses the other major cellular protein degradation pathway, the 
lysosome, to degrade PKR during infection (36). Though the mechanism is unclear, expression 
of the major FMDV protease 3Cpro is required for PKR degradation by the lysosome. However, 
3Cpro does not interact with PKR, nor is its protease activity required for PKR degradation. The 
enterovirus A71 3Cpro causes PKR degradation by direct interaction (39). The mechanism of 
	 35 
PKR depletion by poliovirus is unclear, though gene expression is required, and the major 
poliovirus proteases (2A and 3C) are not directly involved (33). The mechanism by which 
mengovirus depletes PKR during infection is unknown (37, 38).  
Adenoviruses are species-specific, making the study of hAd pathogenesis difficult in an 
animal model. MAV-1 is a useful alternative to study adenovirus pathogenesis (42-46). MAV-1 
has molecular, genetic, and pathogenic similarities and differences to hAd. Their genomic 
structures are similar at a gross level, and both contain early genes involved in pathogenesis and 
immune evasion. Pathogenically, their tropisms vary, with hAd infecting epithelial cells, leading 
to upper respiratory and GI tract infections, and conjunctivitis, while MAV-1 infects endothelial 
cells and monocytes, causing encephalitis and myocarditis. We and others have been 
investigating the adaptive and innate immune responses to MAV-1. 
HAd VA RNAs bind PKR as a monomer, preventing its transautophosphorylation (47). 
However, MAV-1 does not produce VA RNAs (48), and it is not known whether MAV-1 
induces PKR activation. In our studies of MAV-1 pathogenesis and the innate response, we 
discovered that during MAV-1 infection, PKR was depleted from cells as early as 12 hours post 
infection (hpi). Total PKR mRNA levels and PKR mRNA bound to polysomes were unchanged 
or increased during MAV-1 infection, suggesting that MAV-1 did not appear to be targeting 
PKR at a transcriptional or translational level. However, inhibiting the proteasome blocked the 
PKR depletion seen in MAV-1-infected cells, indicating that proteasomal degradation is 
responsible for PKR depletion during MAV-1 infection. We report results indicating that an 
early viral gene is likely responsible for mediating PKR degradation. To our knowledge, this is 
the first example of a DNA virus counteracting PKR by degrading it. 
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Results  
Viral yield is increased in PKR-/- mouse embryonic fibroblasts 
While PKR is an important part of the innate immune response, PKR-/- cells in culture are 
not always more susceptible to viral infection than wild type cells (49-51). PKR-/- mouse 
embryonic fibroblasts (MEFs) show increased viral yields compared to wild type MEFs when 
infected with vesicular stomatitis virus and influenza A (49, 50), but there is no change in viral 
yield during vaccinia virus infection compared to wild type cells (51). However, it was later 
discovered that the PKR-/- MEF lines used are not complete PKR knockouts (52). There are two 
categories of PKR-/- MEFs derived from knockout mice: N-PKR-/- MEFs and C-PKR-/- MEFs 
(pronounced N minus or C minus MEFs) (Fig. 2.1) (52). The PKR-/- MEFs derived from mice 
created in the Weissmann lab (53) are designated N-PKR-/- MEFs, because the C-terminal 
fragment of PKR is still expressed and can be detected by immunoblot when there is IFN 
induction (52). The fragment has the kinase catalytic activity of PKR, but it does not bind 
dsRNA (52). The PKR-/- MEFs derived from mice created in the Bell lab (54) are designated as 
C-PKR-/- MEFs, because the N-terminal fragment of PKR is still expressed and can be detected 
by immunoblot with specific PKR antibodies (52). The fragment is catalytically inactive, but it 
can still bind dsRNA (52). Susceptibility of these PKR-/- MEFs to specific viruses may be 
dependent on the PKR mutation and the mechanism used by each virus to circumvent PKR. 
To determine whether PKR plays an important role during MAV-1 infection, we tested 
the susceptibility of both PKR-/- MEF lines and primary peritoneal macrophages from N-PKR-/- 
mice to MAV-1 infection. We infected wild type MEFs, N-PKR-/- MEFs, C-PKR-/- MEFs, 
C57BL/6 (wild type) macrophages, and N-PKR-/- macrophages with MAV-1 at an MOI of 1 and 
collected cell pellets at 24, 48, and 72 hpi. DNA was purified from the cell pellets and analyzed  
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Figure 2.1 Fragments of PKR protein expressed in PKR-/- MEFs, adapted from Figure 1A and 5B from 
Baltzis et al. As described in Baltzis et al., 2002, the two PKR-/- MEF lines each expresses a fragment of 
PKR. The N-PKR-/- MEFs express a C-terminal fragment that has kinase activity, but no dsRNA binding 
activity. The C-PKR-/- MEFs express a N-terminal fragment that has dsRNA binding activity, but no kinase 
activity.
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for MAV-1 genome copies by qPCR. N-PKR-/- MEFs produced a significantly higher viral yield 
than wild type MEFs at 48 hpi, and both PKR mutant MEF lines had a significantly higher viral 
yield than wild type MEFs at 72 hpi (Fig. 2.2A). In the peritoneal macrophages, virus yield was 
almost doubled in the N-PKR-/- macrophages compared to the wild type macrophages by 72 hpi 
(Fig. 2.2B). Although we have not confirmed the production of truncated PKR proteins in the 
cells in our laboratory, the results of Fig. 2.2 indicate that PKR activation is an important 
antiviral response during MAV-1 infection in vitro.  
 
There is little difference in survival between N-PKR-/- and wild type mice 
Using the N-PKR-/- mice (53), we assayed whether PKR has an antiviral function during 
MAV-1 infection in vivo. We infected N-PKR-/- and C57BL/6 (wild type) mice intraperitoneally 
with 5x101, 101, 102, or 103 PFU MAV-1, and survival was recorded for 21 days post infection. At 
5x101, 101, and 103 PFU, there was no significant difference in survival rates between N-PKR-/- 
and wild type mice, and at 102 PFU, the N-PKR-/- mice had a significantly higher survival rate than 
the wild type mice (Fig. 2.3). These results suggest that in vivo, there are few effects of the N-PKR 
mutation. This could be due to residual PKR protein being made, or there may be redundancies 
between PKR and the other three eIF2a kinases. 
 
Mouse PKR is depleted during MAV-1 infection 
To determine whether MAV-1 affects PKR during infection, we infected several cell 
types and analyzed PKR protein expression. We infected immortalized C57BL/6 MEFs, 
C57BL/6 primary peritoneal macrophages, and CMT93 cells (mouse rectal carcinoma cells) with 
MAV-1 at an MOI of 10 and collected cell lysates 24, 48, and 72 hpi. We analyzed cell lysates  
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Figure 2.2 Viral yield is increased in PKR-/- mouse embryonic fibroblasts and peritoneal macrophages. (A)
PKR WT MEFs (WT), N-PKR-/- MEFs (N-), and C-PKR-/- MEFs (C-) or (B) primary peritoneal macrophages 
from C57BL/6 (B6) or PKR-/- mice were infected with MAV-1 at MOI 1 and collected at 48 and 72 hpi. DNA 
was purified from cell pellets and analyzed for MAV-1 genome copies by qPCR. Both graphs are 
representative of three experiments, (A) 14 or (B) 18 biological replicates per cell line per time point. Error 
bars are standard error of the mean (SEM). *P ≤ 0.05, ***P ≤ 0.0002, ****P ≤ 0.0001.
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Figure 2.3 Survival during MAV-1 infection is increased or unchanged in PKR-/- mice compared to wild-
type mice. Wild-type mice (C57BL/6) and PKR-/- mice were infected intraperitoneally with (A) 101 pfu 
MAV-1, (B) 5x101 pfu MAV-1, (C) 102 pfu MAV-1, or (D) 103 pfu MAV-1 and survival was recorded for 
21 days. **P ≤ 0.01. The data shown are pooled from independent experiments. The number of mice in each 
group is listed next to the line label.
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for the presence of PKR by immunoblot using a polyclonal antibody that detects mouse PKR. 
We probed blots with antibodies to actin as a loading control. To our surprise, in C57BL/6 
MEFs, PKR was almost completely depleted from lysates 24 hpi and remained depleted through 
72 hpi (Fig. 2.4A and B). We also observed depletion of PKR in other cell types. In CMT93 
(mouse rectal carcinoma) cells, PKR was nearly undetectable at 24 hpi (Fig. 2.4A). In C57BL/6 
primary peritoneal macrophages, PKR was decreased at 48 hpi compared to mock lysates, and 
absent in infected lysates at 72 hpi (Fig. 2.4A). This indicates that MAV-1 causes PKR depletion 
during infection.  
To determine whether kinase activity of PKR is important for the depletion, we assayed 
infection of MEFs expressing a mutant form of mouse PKR with a point mutation in the kinase 
domain (K271R) (55). These cells, designated K271R SV40-MEFs, showed an even more rapid 
depletion of PKR than in WT SV40-MEFs (Fig. 2.4C). At 24 hpi, in K271R SV40-MEFs, 28% 
of PKR remained, compared to 60% in the WT SV40-MEFs. The fraction remaining at 72 hpi in 
K271R SV40-MEFs was 10%, compared to 30% in WT SV40-MEFs (Fig. 2.4C). This indicates 
that the PKR kinase does not have to be functional to be depleted during MAV-1 infection. Also, 
comparing the PKR immunoblot bands in the mock-infected WT SV40 MEFs and mutant 
K271R SV40-MEFs suggests that the upper band of the PKR doublet usually seen in wild type 
cells is a phospho-PKR band, because only the lower band of the PKR doublet is seen in kinase-
dead mutant K271R SV40-MEFs. The data in Fig. 2.4A and C thus indicate that both PKR and 
phospho-PKR are depleted during MAV-1 infection. 
 
 
 
	 42 
 
 
 
 
 
 
 
 
actin
mock     MAV    mock   MAV    mock     MAV 
24 hpi 48 hpi 72 hpi
PKR
C57BL/6
MEFs
C57BL/6
macrophages
CMT93
actin
PKR
actin
PKR
Figure 2.4 Mouse PKR is depleted during MAV-1 infection. (A) Cells (indicated at left) were infected with 
MAV-1 (MAV) at an MOI of 10 or mock infected (mock). Cell lysates were collected at the indicated times 
and analyzed by immunoblot with antibodies for PKR (B-10 for C57BL/6 MEFs and D-20 for C57BL/6 
primary peritoneal macrophages and CMT93 cells) and actin. Blots are representative of a minimum of three 
independent experiments per cell line. (B) Densitometry quantitation of five C57BL/6 MEFs immunoblots 
from A. Error  bars are SEM. N=5 for 24 hpi, n=4 for 48 hpi, and n=2 for 72 hpi. **P ≤ 0.01. (C) SV40-MEFs 
or kinase-dead (K271R) SV40-MEFs were infected with MAV-1 at an MOI of 10. Cell lysates were 
immunoblotted as in A with PKR D-20. Numbers below are the proportion of PKR protein for each time 
point, normalized to actin and the mock PKR protein levels from the corresponding time point. 
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huPKR is not degraded by MAV-1 
Mouse PKR and human PKR share 58% amino acid identity and are 71% similar. To 
determine whether MAV-1 depletes human PKR in a manner similar to mouse PKR, we used 
PKR-/- MEFs transfected to constitutively express FLAG-tagged full length, kinase-dead, or 
RNA binding-deficient human (hu) PKR (56). We infected each of these cell lines with MAV-1 
at an MOI of 10, collected lysates at 72 hpi, and analyzed huPKR protein levels by immunoblot 
with antibodies to FLAG. Human PKR was not depleted at any time point during infection, and 
in fact levels of all three huPKR types were increased in infected lysates compared to mock 
lysates at 72 hpi (Fig. 2.5A). This suggests that the depletion of mouse PKR is species-specific 
and that a region of mouse PKR sequence not found in human PKR may be a determinant. 
To confirm MAV-1 was replicating successfully in all three of these cell lines, we 
infected the vector, full length, kinase-dead, or RNA binding-deficient human PKR lines with 
MAV-1 at an MOI of 10 and collected cell pellets at 48 and 72 hpi. DNA was purified from the 
cell pellets and analyzed for MAV-1 genome copies by qPCR. The virus replicated efficiently in 
the vector, full length, and RNA binding-deficient huPKR lines, demonstrating that the lack of 
huPKR degradation was not due to a lack of MAV-1 replication in the cell lines (Fig. 2.5B). 
However, MAV-1 replicated poorly in the kinase-dead huPKR line and thus a conclusion cannot 
be drawn about the lack of degradation of the human kinase-dead PKR. The presence of the full 
length huPKR doubled the amount of MAV-1 replication compared to the vector cell line, which 
contained no PKR at all. This could mean that the kinase domain of huPKR increases MAV-1 
infection. We have not investigated this further. 
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Figure 2.5 Human PKR is not depleted during MAV-1 infection. (A) PKR-/- MEFs reconstituted with FLAG-
tagged full length (WT-huPKR), kinase dead (KD-huPKR), or RNA-binding mutant human PKR (RB-
huPKR) (indicated above) were infected with MAV-1 (MAV) at an MOI of 10 or mock infected (mock). Cell 
lysates were collected at the indicated times and analyzed by immunoblot with antibodies for FLAG and 
actin. Blots are representative of a minimum of three independent experiments per cell line. (B) PKR-/- MEFs 
reconstituted with FLAG-tagged full length, kinase dead, or RNA-binding mutant human PKR were infected 
with MAV-1 at MOI 10 and collected at 48 and 72 hpi. DNA was purified from cell pellets and analyzed for 
MAV-1 genome copies by qPCR. Both graphs are representative of three experiments, 17-19 biological 
replicates per cell line per time point. Error bars are SEM. *P ≤ 0.05, ***P ≤ 0.0002, ****P ≤ 0.0001.
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MAV-1 does not cause PKR depletion by reducing steady-state levels of PKR mRNA  
To determine the mechanism of PKR depletion, we first assayed whether reduction in 
PKR protein during MAV-1 infection was due to reduced PKR mRNA steady-state levels. We 
mock-infected or infected C57BL/6 MEFs and primary peritoneal macrophages at an MOI of 10 
and collected cell lysates at 24, 48, and 72 hpi. We synthesized cDNA from RNA purified from 
these cell lysates and assayed for PKR mRNA by qPCR. In C57BL/6 MEFs, PKR mRNA levels 
were similar between mock and infected lysates at 24 hpi (Fig. 2.6A), a time point in which PKR 
protein levels were already greatly depleted in the infected lysates compared to mock lysates 
(Fig. 2.4A). Although PKR mRNA levels were depleted 33% at 48 hpi and 40% 72 hpi in 
MAV-1-infected lysates compared to mock lysates, this does not correlate to the 84% and 94% 
reduction, respectively, in PKR protein levels at those time points. In C57BL/6 primary 
peritoneal macrophages, PKR mRNA levels in the infected lysates were 2-3 times higher than 
levels in mock lysates at all three time points assayed (Fig. 2.6B), even though PKR protein 
levels were almost completely depleted in infected lysates at 72 hpi (Fig. 2.4A). This is evidence 
that MAV-1 is not causing PKR protein depletion by reducing PKR steady-state mRNA levels 
during infection. 
 
MAV-1 infection effects on PKR translation 
Because MAV-1 did not reduce PKR mRNA steady-state levels, we determined whether 
MAV-1 causes PKR depletion by reducing translation of its mRNA. We first assayed total PKR 
mRNA bound to ribosomes during infection. C57BL/6 MEFs were mock infected or infected at 
an MOI of 5, and lysates were collected at 48 hpi in the presence of cycloheximide to keep the 
mRNA bound to the ribosomes (57). Lysates were centrifuged through 25% sucrose to pellet  
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Figure 2.6 MAV-1 does not cause PKR depletion by reducing steady state levels of PKR mRNA at times 
when the protein levels are already reduced. MEFs (A) or isolated primary peritoneal macrophages (B) were 
harvested and infected with MAV-1 at an MOI of 10 or mock infected. The cell pellets were collected and 
RNA was isolated. cDNA was generated from the RNA, and qPCR was used to quantitate PKR mRNA levels. 
Each graph contains 5-7 replicates for each time point from three pooled experiments. Error bars are SEM. 
*P ≤ 0.05 and **P ≤ 0.01.
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Figure 2.7 MAV-1 infection does not affect PKR translation. (A) C57BL/6 MEFs were infected with MAV-1 
(MAV) at an MOI of 5 or mock infected (mock) and collected at 48 hpi. Cells were lysed, and cleared lysates 
from three 10 cm plates were layered onto 25% sucrose and centrifuged to pellet ribosomes. RNA was 
purified from the pellets, cDNA was generated from the RNA, and qPCR was used to quantitate the PKR 
mRNA levels. The graph contains 9 replicates for each time point, pooled from 3 independent experiments. 
Error bars show the SEM. (B) To confirm that most ribosomes ended up in the pellet after centrifugation 
through sucrose, a sample of the pellet and the corresponding supernatant were analyzed by immunoblot with 
antibodies for RPL7 (ribosomal protein L7, Abcam, 1:2000, ab72550). (C) C57BL/6 MEFs were infected 
with MAV-1 (MAV) at an MOI of 2 or mock infected (mock). Cells were collected at 25 hpi and lysed; 
cleared lysates were layered onto 10-50% sucrose gradients and centrifuged. Gradients were collected from 
the top and pumped through a UV spectrophotometer, and 34 fractions were collected. The gradients are 
displayed with the bottom fractions to the right. The UV trace of the first 10 fractions (including 40S and 60S 
ribosomal subunits) is not shown. (D) RNA was purified from each fraction of the gradients in B; fractions 
are renumbered here with the first fraction corresponding to fraction 11 of the original gradient. cDNA was 
generated from the RNA, and qPCR was used to quantitate PKR mRNA in each fraction and displayed as the 
percent of total PKR mRNA associated with ribosomes. C and D are results from one representative 
experiment of 3 independent experiments. (E) Percentage of total PKR mRNA associated with monosomes 
(fractions 1-6) and polysomes (fractions 7-19) from the trial displayed in C and D were pooled for mock and 
infected samples. The percentages represented by each bar are displayed below each bar. (F) Pooled 
monosome and polysome data as described in E from three independent experiments. Error bars are SEM. 
The percentages represented by each bar are displayed below each bar. There were no significant differences 
between mock and infected samples (A, F).
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ribosomes, and RNA was purified from the pellets. The purified RNAs were used to generate 
cDNA, which we assayed for PKR mRNA by qPCR (Fig. 2.7A). As a control for pelleting of 
ribosomes, we assayed the pellets and sucrose cushion supernatants by immunoblot with 
antibodies to ribosomal protein RPL7. We confirmed that RPL7 was only present in the pellets 
and not the supernatants (Fig. 2.7B). There was no significant difference between the amount of 
PKR mRNA in the ribosome pellet of mock infected lysates compared to MAV-1-infected 
lysates (Fig. 2.7A).  
To confirm the results seen in total mRNA bound to ribosomes, we also centrifuged cell 
extracts on sucrose gradients to generate polysome profiles. This enabled us to analyze levels of 
PKR mRNA associated with actively-translating ribosomes during infection. C57BL/6 MEFs 
were mock infected or infected at an MOI of 2, and lysates were collected at 24 hpi in the 
presence of cycloheximide, as above. RNA content for mock and infected lysates was estimated 
by NanoDrop spectrophotometry, and equivalent OD amounts of RNA were centrifuged on 
10-50% sucrose gradients to sediment 40S and 60S ribosomal subunits, 80S ribosomes 
(monosomes), and polyribosomes (polysomes). A typical polysome profile was obtained (Fig. 
2.7C). RNA was purified from fractions containing monosomes and polysomes and then used to 
generate cDNA, which we assayed for PKR mRNA by qPCR (Fig. 2.7D). As a control, GAPDH 
mRNA was measured by qPCR, and PKR mRNA levels in each fraction were normalized to the 
GAPDH mRNA content. When the data for percentage of PKR mRNA bound to ribosomes was 
pooled into monosome and polysome fractions and analyzed (Fig. 2.7E), 90.1% and 91.8% were 
bound to polysomes (fractions 7-19) for mock and infected samples, respectively, compared to 
9.9% and 8.2% bound to monosomes (fractions 1-6). We performed two additional polysome 
gradient analyses. The pooled data from all three (Fig. 2.7F) were similar to the data for Fig. 
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2.7E, i.e., 82.7% and 92.7% of PKR mRNA was bound to mock and infected polysomes, 
respectively, compared to 17.3% and 7.3% bound to monosomes. Thus, PKR protein depletion 
during MAV-1 infection does not appear to stem from a decrease in PKR mRNA translation.  
We also assayed whether PKR mRNA might have a signal that would reduce its 
translation during MAV-1 infection. We constructed a plasmid that positioned sequence 
corresponding to the 5' UTR of PKR mRNA upstream of a reporter nanoluciferase gene (58), 
transfected it into C57BL/6 MEFs or CMT93 cells, then infected with MAV-1 at MOI of 10. 
Compared to cells transfected with a control plasmid with the human b-globin 5' UTR upstream 
of the reporter nanoluciferase, there was no significant difference in luciferase activity between 
mock infected and infected samples (Fig. 2.8). These data suggest that MAV-1 is not affecting 
PKR translation through interaction with the 5' UTR of PKR. The data are consistent with the 
ribosome pellet and polysome data that MAV-1 infection does not reduce PKR mRNA 
translation. 
 
PKR is depleted by proteasomal degradation during MAV-1 infection 
There are two main proteolysis pathways in cells, proteasomal degradation and lysosomal 
degradation (59). To determine whether MAV-1 depletes PKR by either protein degradation 
pathway, we first assayed whether PKR is lysosomally degraded as follows. CMT93 cells were 
mock infected or infected with MAV-1 and treated at the time of infection with the lysosome 
inhibitors ammonium chloride or chloroquine, or water (as a control). At 24 hpi, we collected 
lysates and analyzed them by immunoblot with antibodies to PKR. In the presence of the 
lysosomal degradation inhibitors, PKR was depleted by 24 hpi (Fig. 2.9A), indicating that 
lysosomal degradation was not the cause of PKR depletion during MAV-1 infection.  
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A B
Figure 2.8 PKR mRNA 5' UTR does not result in altered reporter protein levels upon MAV-1 infection. (A) 
C57BL/6 MEFs or (B) CMT93 cells were co-transfected with pmPKR5UTRfullNL or AUG-NL-3xFLAG and 
pGL4.13 using jetPRIME reagents (Polyplus #114-01) using the standard Polyplus protocol, with 200 ng total 
of plasmid and 300 µL of jetPRIME reagent per 35 mm well. At 24 hours after transfection, the cells were 
infected with MAV-1 at an MOI of 10. At 24 hpi, cells were lysed in 70 µL/well Glo Lysis Buffer (Promega 
Corp.). After lysing, 25 µL of each lysed sample and 25 µL of OneGlo or NanoGlo (Promega Corp.) was 
added to two wells in a black 96-well plate. After 5 minutes, the plate was read on a luminometer. Relative 
light units from the pmPKR5UTRfullNL plasmid were normalized to the firefly luciferase and positive 
control plasmids. Graphs are representative of 7-9 biological replicates per treatment group. Error bars are 
SEM.
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Figure 2.9 PKR is not depleted by lysosomal degradation during MAV-1 infection. (A) CMT93 cells were 
infected with MAV-1 (MAV) at an MOI of 10 or mock infected (mock) and treated with 10 mM ammonium 
chloride or 60 µM chloroquine to inhibit lysosomal degradation, or water, as a control. Cell lysates were 
analyzed by immunoblot with antibodies for PKR (D-20) and actin. Blots are representative of three 
independent experiments. (B) Inhibitors were tested for activity using a DQ BSA assay; the DQ BSA 
molecule will only fluoresce if lysosomal degradation is functional. Uninfected cells were treated as indicated 
and imaged by fluorescence microscopy.
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We confirmed that the inhibitor treatment did block lysosomal degradation by incubating cells 
with dye-quenched bovine serum albumin (DQ BSA) in addition to the lysosomal inhibitors. DQ 
BSA is self-quenched until it is digested in the lysosome (60, 61), and imaging confirmed that 
cells treated with lysosome inhibitors did not fluoresce, but cells treated with the vehicle control 
(H2O) did, as expected (Fig. 2.9B). 
Next, we examined whether proteasomal degradation is responsible for the degradation of 
PKR by using proteasome inhibitors MG132 and bortezomib. These inhibit proteasome activity 
by binding to the active sites in the 20S subunit and blocking the proteolytic activity (62-64). We 
mock infected or infected C57BL/6 MEFs with MAV-1 and treated with MG132 or bortezomib 
in DMSO at the time of infection. At 24 hpi, we collected lysates and analyzed them by 
immunoblot for PKR protein levels. While PKR was depleted in the control DMSO-treated 
MAV-1-infected cells as expected, PKR protein was present in the MG132- and bortezomib-
treated cells at levels comparable to mock infected cells (Fig. 2.10A and B). To rule out the 
possibility that PKR was present (not depleted) because the virus infection itself was inhibited by 
MG132 or bortezomib, we assayed viral replication of MAV-1 with MG132 and bortezomib 
treatment by qPCR of viral DNA. Viral replication was equivalent in all three treatment groups 
(Fig. 2.10C), indicating that the treatments did not affect the ability of the virus to productively 
infect the cells. Taken together, these data indicate that MAV-1 infection results in PKR 
depletion by causing PKR to be degraded by the proteasome during infection. This protection of 
PKR protein levels by proteasome inhibitors was only effective if the proteasome inhibitors were 
added at an early time point of infection, prior to 24 hpi. When proteasome inhibitors were added 
at times when PKR protein levels were already significantly reduced (e.g., 24 hpi, lanes 6, 8, 12,  
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Figure 2.10 PKR is depleted by proteasomal degradation during MAV-1 infection. (A) C57BL/6 MEFs were 
infected with MAV-1 (MAV) at an MOI of 10 or mock infected (mock) and treated with DMSO (vehicle for 
inhibitors), 1 µM MG132, or 1 µM bortezomib. Cell lysates were analyzed by immunoblot with antibodies 
for PKR (D-20) and actin. Blots are representative of four independent experiments. (B) Densitometry 
quantitation of four independent experiments. Treatment with bortezomib significantly inhibited PKR 
depletion in MAV-1 infected cells, *P ≤ 0.05. (C) MG132 and bortezomib treatments do not affect MAV-1 
replication at 24 hpi. C57BL/6 MEFs were infected with MAV-1 at an MOI of 10 and treated with DMSO 
(vehicle for inhibitors), 1 µM MG132 or bortezomib, and collected at 24 hpi. DNA was purified from cell 
pellets and analyzed for MAV-1 genome copies by qPCR. Graph is representative of five biological replicates 
per treatment group. Error bars are SEM. *P ≤ 0.05 
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Figure 2.11 Delayed proteasome inhibition does not prevent PKR depletion during MAV-1 infection. 
C57BL/6 MEFs were infected with MAV-1 (MAV) at an MOI of 10 or mock infected (mock) and treated with 
DMSO (vehicle for inhibitors), 1 µM MG132, or 1 µM bortezomib at 0 or 24 hpi. Cell lysates were were 
analyzed by immunoblot with antibodies for PKR (D-20) and actin. Blots are representative of four 
independent experiments. 
Treatment added:      None              0 hpi            24 hpi          24 hpi            0 hpi          24 hpi           24 hpi
Lane number:          1          2        3        4         5        6        7         8       9       10      11       12 13     14
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14), there was no protective effect from the proteasome inhibitors, even when cells were 
subsequently treated for a full 24 hours (lanes 8, 14) (Fig. 2.11). 
 
PKR is not detectably ubiquitinated during MAV-1 infection 
A signal for proteasomal degradation is the conjugation of ubiquitin to a protein (65, 66). 
We examined whether PKR is ubiquitinated, assaying by immunoprecipitation and immunoblot. 
We also assayed the ubiquitination of a positive control, mouse p53, which is degraded in the 
presence of MAV-1 proteins (67). We transfected CMT93 cells with a GFP-tagged ubiquitin 
(68), and at 24 hours post transfection (hpt), we infected them with MAV-1 at an MOI of 5 or 
mock infected. Cells were treated with MG132 at 6 hours prior to harvest to prevent complete 
PKR degradation. Lysates were immunoprecipitated with PKR (D-20), p53 (DO-1), or 
corresponding isotype antibodies. The immunoprecipitated samples were analyzed by 
immunoblot with antibodies to GFP, ubiquitin, PKR (B-10), p53 (1801), or corresponding 
isotype antibodies (Fig. 2.12A and B). Ubiquitination of p53 was readily evident (Fig. 2.12B). 
However, even with the use of epitope-tagged ubiquitin, we were unable to detect PKR 
ubiquitination during infection (Fig. 2.12A). This is consistent with an inability to detect PKR 
ubiquitination when it is degraded during RVFV infection (32). Although RVFV NSs is known 
to recruit an E3 ligase to PKR, the authors reported that ubiquitinated PKR is undetectable. 
Therefore, the cellular degradation signal for PKR remains unclear.  
 
PKR is actively depleted early in infection 
We investigated when proteasomal degradation of PKR occurs. Early viral proteins are 
expressed prior to viral DNA replication, which is then followed by late viral protein expression.  
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Figure 2.12 PKR is not detectably ubiquitinated during MAV-1 infection. CMT93 cells were transfected with 
a GFP-ubiquitin plasmid using standard Polyplus transfection protocols. At 24 hpt, the cells were infected 
with MAV-1 (MAV) at an MOI of 5 or mock infected (mock) and treated with 10 µM MG132 at 6 hpi. Cell 
lysates were collected at 12 hpi and immunoprecipitated with (A) PKR (D-20) or an isotype control antibody 
or (B) p53 (DO-1) or an isotype control antibody. Immunoprecipitated samples were analyzed by immunoblot 
with GFP, ubiquitin, isotype, PKR (B-10), or p53 (1801) antibodies. Input lane (mock input) contains 0.008 
volume of mock infected lysate (relative to volume in immunoprecipitations). For (B) GFP and p53 were 
probed on separate duplicate blots.
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First, we examined the kinetics of PKR degradation to determine whether an early or late 
viral protein was likely responsible. We mock infected and infected CMT93 cells with MAV-1 at 
an MOI of 10 and collected lysates every six hours for 24 hours and analyzed them by 
immunoblot with antibodies to PKR or MAV-1 early region 1A (E1A) protein, the first viral 
protein made during infection (69). In infected cells, PKR degradation was first detected at 12 
hpi (Fig. 2.13A), and quantitation of five independent experiments showed that ~20% of the 
starting levels of PKR protein remained at 24 hpi (Fig 2.13B). 
In parallel, to determine the half-life of PKR in uninfected CMT93 cells, we treated 
CMT93 cells with cycloheximide to halt protein translation and thus production of new PKR. 
We collected lysates every six hours for 24 hours and analyzed by immunoblot with antibodies 
to PKR. After 24 hours of cycloheximide treatment, approximately 90% of the starting levels of 
PKR protein remained (Fig. 2.13A bottom, and B). Comparing the results from MAV-1 infection 
(Fig. 2.13A top, and 2.13B) and cycloheximide treatment of uninfected cells (Fig. 2.13A bottom, 
and 2.13B), we conclude that MAV-1 was actively depleting PKR protein early in infection. 
E1A was detected by immunoblot at 18 hpi (Fig. 2.13C), whereas viral DNA replication was first 
detected at 24 hpi in CMT93 cells (Fig. 2.14). Thus the 18 hpi timepoint is considered an early 
time point during MAV-1 infection of CMT93 cells, prior to DNA replication, suggesting the 
involvement of an early viral protein in PKR depletion. 
 
An early viral function is required for PKR depletion by MAV-1 
To determine whether viral gene expression or DNA replication are required for PKR 
degradation during infection, we infected C57BL/6 MEFs and CMT93 cells with UV-inactivated 
MAV-1 (which does not replicate, Fig. 2.15C and D). We infected cells at an MOI of 10 with  
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Figure 2.13 PKR is actively depleted early in infection. (A) CMT93 cells were infected with MAV-1 (MAV) 
at an MOI of 10 or mock infected (mock) (top), or uninfected cells were treated with 50 µg/mL 
cycloheximide (CHX, bottom) to inhibit elongation of protein synthesis. Cell lysates were analyzed by 
immunoblot with antibodies for PKR (D-20) and actin. Blots are representative of five independent 
experiments. (B) Densitometry quantitation of five independent experiments. Error bars are SEM. **P ≤ 
0.01. (C) CMT93 cell lysates from A were analyzed with a second immunoblot with antibodies for E1A and 
actin. Blots are representative of four replicates from two independent experiments. 
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Figure 2.14 Viral replication can be detected at 24 hpi by qPCR. CMT93 cells were infected with MAV-1 
(MAV) at an MOI of 10 and collected every 6 hours for 24 hours. DNA was purified from cell pellets and 
analyzed for MAV-1 genome copies by qPCR. Graph is representative of four to five biological replicates per 
treatment group. Error bars are SEM.
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Figure 2.15 Early gene expression is required for PKR depletion by MAV-1. (A) Cells (as indicated at left) 
were infected with WT MAV-1 (WT MAV) or UV-inactivated MAV-1 (UV MAV) at an MOI of 10, or mock 
infected (mock). Cell lysates were analyzed by immunoblot with antibodies for PKR (D-20) and actin. Two 
independent wells were infected for each condition at both time points. (B) CMT93 cells were infected with 
WT MAV-1 (MAV) at an MOI of 10 or mock infected (mock). Infected cells were also treated (+) or not (-) 
with 20 µg/mL cytosine arabinasine (AraC), an inhibitor of DNA synthesis. Cell lysates were analyzed with 
antibodies for PKR and actin. (C) UV-inactivated virus does not replicate. C57BL/6 MEFs or (D) CMT93 
cells were infected with WT MAV-1 (WT) or UV-inactivated MAV-1 (UV) at an MOI of 10 and collected at 
indicated times. DNA was purified from cell pellets and analyzed for MAV-1 genome copies by qPCR. 
Graphs are representative of three to four biological replicates per treatment group. Error bars are SEM. (E) 
AraC treatment inhibited late protein expression. CMT93 cells were infected with WT MAV-1 (MAV) at an 
MOI of 10 or mock infected (mock). Infected cells were also treated (+) or not (-) with 20 µg/mL cytosine 
arabinasine (araC), an inhibitor of DNA synthesis. Cell lysates were analyzed with antibodies for late virion 
proteins (AKO1-103, 1:1000). Arrowheads indicate late viral proteins.
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WT MAV-1 or UV-inactivated MAV-1 and analyzed lysates from 24 and 48 hpi by immunoblot 
for PKR protein levels. In both cell types, while PKR was degraded by 24 hpi in the cells 
infected with WT MAV-1, PKR protein levels were unaffected at both time points in cells 
infected with UV-inactivated MAV-1 (Fig. 2.15A). This suggested that either gene expression or 
DNA replication was required for PKR degradation during MAV-1 infection. 
We addressed whether viral DNA replication is needed for PKR degradation. We mock 
infected or infected CMT93 cells with MAV-1 at an MOI of 10 and treated them with cytosine 
arabinoside (araC) at the time of infection to inhibit DNA synthesis (70, 71). This would allow 
the virus to infect the cell and produce early viral proteins, but would inhibit viral DNA 
replication and prevent late protein synthesis. We collected lysates at 20 and 40 hpi and analyzed 
them by immunoblot. We confirmed that araC treatment resulted in no late protein synthesis by 
performing an immunoblot for late virion proteins (Fig. 2.15E). In samples treated with araC, 
PKR degradation was seen at 20 and 40 hpi (Fig. 2.15B), indicating that DNA replication was 
not required for PKR degradation. Taken together, the results of Fig. 2.15 are consistent with 
early viral gene expression prior to DNA replication being involved in induction of PKR 
degradation by MAV-1.  
 
E1A and E3 are not required for PKR degradation during MAV-1 infection 
To investigate the early gene responsible for PKR degradation during MAV-1 infection, 
we used two mutant viruses, E1A- and E3-, which replicate successfully but do not express the 
specified early gene products (69, 72). We infected C57BL/6 primary peritoneal macrophages 
and C57BL/6 MEFs with wild type MAV-1, E1A- MAV-1, or E3- MAV-1 at an MOI of 5 and 
analyzed lysates from 24, 72, and 96 hpi by immunoblot for PKR protein levels. In the  
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Figure 2.16 E1A and E3 are not required for PKR degradation during MAV-1 infection. (A) C57BL/6 
primary peritoneal macrophages or (B) C57BL/6 MEFs were infected with WT MAV-1 (WT), E1A- mutant 
MAV-1 (E1A-), or E3- mutant MAV-1 (E3-) at an MOI of 10, or mock infected (mock). Cell lysates were 
analyzed by immunoblot with antibodies for PKR (D-20) and actin. 
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macrophages, PKR protein was still present at 72 hpi in the cells infected with the E1A- virus, 
though at levels lower than in mock infected macrophages (Fig. 2.16A). This could mean that 
E1A is required for PKR degradation, but it could also just be a result of slower infection, 
because the E1A mutant virus demonstrates slower growth kinetics compared to wild type 
MAV-1 (73). We examined PKR protein levels in C57BL/6 MEFs after 96 hpi with wild type, 
E1A-, and E3- MAV-1. In C57BL/6 MEFs, PKR was completely degraded by all three viruses by 
96 hpi, suggesting that neither E1A nor E3 is required for PKR degradation during MAV-1 
infection (Fig. 2.16B). 
 
Discussion 
We have demonstrated here that PKR is antiviral in MAV-1 infections of cultured cells. 
Surprisingly, MAV-1 infection of primary and established cultured cells depleted PKR. The 
depletion was not due to reduced steady-state levels or reduced translation of PKR mRNA. 
Instead, we showed that PKR depletion is inhibited by proteasome inhibitors, implicating 
proteasomal degradation of PKR. Several lines of evidence suggest that the degradation is due to 
a viral early function. 
PKR is an IFN-inducible gene product that is an important component of the innate 
immune response (1, 49). However, not all viruses have increased virulence in PKR-/- MEFs, 
including EMCV and vaccinia virus (51, 74). While hAds produce VA RNAs that inhibit PKR 
antiviral activity during infection (10, 75), MAV-1 does not produce such VA RNAs, and how 
MAV-1 infection is affected by PKR is first described in this report. When we infected PKR-/- 
MEFs with MAV-1, viral yields were 5 to 6 times higher than viral yields from wild type MEFs 
(Fig. 2.2A), indicating that PKR plays an antiviral role during MAV-1 infection. At 48 hpi, the 
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viral yield from the N-MEFs (cells lacking the N terminal region dsRNA binding domain of 
PKR) was nearly 4 times higher than the C-MEFs (cells lacking the C terminal region kinase 
domain of PKR), but by 72 hpi the viral yields from both types of PKR-/- MEFs were similar to 
each other and significantly increased compared to wild type MEFs (Fig. 2.2A). This difference 
in viral replication kinetics between the two types of PKR-/- MEFs may be due to differences in 
expression level and activity of the PKR fragments reportedly produced by them; we have not 
assayed PKR fragment production in our cells.  
N-PKR-/- peritoneal macrophages were also more susceptible to MAV-1 infection at 72 
hpi than wild type peritoneal macrophages. The viral yield in N-PKR-/- peritoneal macrophages 
was nearly twice that in wild type peritoneal macrophages. Taken together, these data suggest 
that PKR activation is an important antiviral response to MAV-1 in multiple cell types. However, 
in vivo, N-PKR-/- mice did not have reduced survival compared to wild type mice when infected 
with MAV-1 (Fig. 2.3). Thus, while PKR likely plays a significant antiviral role is specific 
tissues, there may be redundancies in the PKR signaling pathway that compensate when PKR is 
not present or is inactivated. Alternatively, since N-PKR-/- mice may express a PKR fragment 
with kinase activity (52), it is possible that this fragment provides enough PKR activity to protect 
the mice from MAV-1 infection. However, we have not examined in vivo expression of this 
fragment. 
We examined PKR protein levels during MAV-1 infection and found that PKR was 
depleted from the cells as early as 12 hpi (Fig. 2.13A). Depletion was seen in a wide variety of 
cell types, including immortalized C57BL/6 MEFs, primary C57BL/6 peritoneal macrophages, 
and CMT93 mouse colon carcinoma cells (Fig. 2.4A). Once depleted, PKR protein levels never 
returned to mock infected PKR protein levels during infection. Activation (phosphorylation) of 
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PKR (6-9) was not required for this depletion, because kinase-dead mouse PKR was also 
depleted from K271R SV40-MEFs during infection (Fig. 2.4C). Both PKR and phospho-PKR 
were depleted in all cell types examined. huPKR was not depleted by MAV-1 (Fig. 2.5A). This 
suggests that MAV-1 degrades PKR by recognizing PKR protein sequence in a region that is 
dissimilar between mouse PKR and human PKR, because the two proteins share only 58% 
amino acid identity overall. This could help in identifying the region of mouse PKR that is 
responsible for its degradation by MAV-1. 
We examined several possibilities that could explain depletion of PKR protein, including 
PKR mRNA levels and alterations in translation. PKR mRNA levels remained unchanged during 
MAV-1 infection in C57BL/6 MEFs at 24 hpi and were increased in primary C57BL/6 peritoneal 
macrophages during MAV-1 infection (Fig. 2.6), times when the PKR protein levels were 
depleted (Fig. 2.4A). While PKR mRNAs in C57BL/6 MEFs were depleted 33% at 48 hpi and 
40% at 72 hpi compared to mock lysates, this is not sufficient to explain the 84% and 94% 
reduction, respectively, in PKR protein levels at those time points (Fig. 2.4B). More likely, the 
reduction in PKR steady-state mRNA levels at the late infection time points can be attributed to 
other effects from viral infection, including the degradation or inhibition of proteins that induce 
PKR expression. For example, p53 is capable of binding to the PKR promoter and inducing its 
expression (76), but MAV-1 proteins cause p53 proteolysis (67). Together our results in 
C57BL/6 MEFs and macrophages suggest the virus does not cause PKR protein depletion by 
reducing PKR steady-state mRNA levels.  
The differences in total PKR mRNA levels during infection between C57BL/6 MEFs and 
primary peritoneal macrophages (Fig. 2.6) is possibly due to the fact that macrophages are an 
immune cell, while MEFs are not. PKR protein took almost 3 times as long to be completely 
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degraded during infection in macrophages compared to MEFs (72 hours versus 24 hours) (Fig. 
2.4A). Total PKR mRNA levels were 2 to 3 times higher in MAV-1-infected macrophages 
compared to mock infected macrophages, unlike the MEFs where total PKR mRNA levels were 
unchanged or reduced 33-40% during MAV-1-infection compared to mock infected MEFs. Since 
PKR is an IFN-stimulated gene (1, 2), higher levels of total PKR mRNA seen during infection in 
the macrophages suggests IFN induction. This suggests that the immune response mounted by 
the macrophages was greater than the immune response in the MEFs, and could help explain 
why PKR took longer to degrade in macrophages compared to MEFs.  
We considered whether reduced PKR levels were due to reduced PKR protein translation. 
There was no change in the total amount of PKR mRNA bound to ribosomes during infection 
compared to uninfected cells, nor was there a significant change in the amount of actively 
translating PKR mRNA during infection (Fig. 2.7). We also found that the 5' UTR of mouse 
PKR placed upstream of a reporter gene produced the same amount of reporter with and without 
MAV-1 infection (Fig. 2.8). These data indicate that there are not translational effects of MAV-1 
infection on PKR protein levels that could explain the depleted PKR levels we observed.  
Inhibiting lysosomal degradation resulted in no change in PKR depletion in infected cells 
(Fig. 2.9A), but adding proteasome inhibitors preserved PKR protein within cells (Fig. 2.10A 
and B). This indicates that PKR is not degraded by lysosomal degradation during viral infection, 
but by proteasomal degradation. However, adding proteasome inhibitors later in infection did not 
have the same protective effect on PKR protein levels as adding them at the start of infection 
(Fig. 2.11). This is consistent with delayed proteasome inhibition experiments with RVFV. 
There, the addition of MG132 prevented p62 degradation by RVFV, but only if MG132 was 
present at the start of infection (77). This is likely due to the fact that MG132 can trigger a 
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reduction in global translation (78, 79). The authors propose that if i) MG132 is added to an 
infection at a time where a specific protein has already been degraded by the proteasome to 
levels unable to detect by immunoblotting, ii) MG132 also reduces protein translation overall, 
and iii) MG132 treatment is not 100% effective at shutting down proteasomal degradation, then 
it is likely that if MG132 is added “too late”, newly synthesized protein could not be stabilized 
by proteasomal inhibition to levels high enough to be detectable by immunoblot. Not only would 
the translation of the protein be reduced, but the proteasome may be functioning just enough to 
continue degrading any small amounts of nascent proteins that are produced. 
Though PKR degradation was due to proteasome activity during MAV-1 infection, we 
were unable to demonstrate PKR ubiquitination (Fig. 2.12A), although we did detect 
ubiquitination of mouse p53 (Fig. 2.12B). This inability to demonstrate PKR ubiquitination 
could be explained if at any given moment there were only low levels of ubiquitinated PKR 
present in the cell. Perhaps, increasing the time under MG132 treatment could increase the 
amounts of ubiquitinated proteins enough so that PKR ubiquitination could be seen. However, 
our inability to detect ubiquitinated PKR is consistent with a similar inability to identify PKR 
ubiquitination by RVFV NSs, even though NSs is known to recruit an E3 ligase to PKR (32). 
Alternatively, it is possible that in MAV-1 infection, PKR is degraded in a ubiquitin-independent 
manner, possibly because of intrinsic disordered regions of PKR or binding of regulating 
proteins to PKR that target proteins to the proteasome (80, 81). 
Our experiments indicate that MAV-1 actively depletes PKR early in infection. Our data 
using mutant MAV-1 viruses suggest that E1A and E3 are not required for PKR degradation 
(Fig. 2.16). Ongoing experiments are focused on determining the MAV-1 early protein(s) 
responsible for PKR degradation. Two possibilities are E4 proteins, the homologs of hAd E4orf6 
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and E4orf3, which we originally termed E4orfa/b and E4orfa/c, respectively (82). In hAd, E4orf6 
interacts with another early hAd protein, E1B 55K, to participate in an E3 ligase complex that 
ubiquitinates and degrades p53 via proteasomal degradation (83, 84). When MAV-1 E4orf6, 
E1B 55K, and mouse p53 are introduced by transfection into human cells, all three proteins 
interact and mouse p53 is degraded (67). If MAV-1 E4orf6 and E1B 55K form a similar complex 
in mouse cells, it may also degrade PKR. We have preliminary evidence that mouse p53 is 
ubiquitinated in C57BL/6 MEFs during MAV-1 infection, which suggests that the mouse p53 
degradation seen in human cells could be paralleled by degradation of endogenous mouse p53 
and mouse PKR in mouse cells, mediated by MAV-1 E4orf6 and E1B 55K during infection. 
Another hAd E4 protein, E4orf3, causes proteasomal degradation of transcriptional intermediary 
factor 1g (85) and general transcription factor II-I (86) in a manner independent of hAd E4orf6 
and E1B 55K. E4orf3	has SUMO E3 ligase and E4 elongase activity and induces sumoylation of 
general transcription factor II-I, leading to its proteasome-dependent degradation (86). MAV-1 
E4orf3 may similarly have sumoylation activity that results ultimately in proteasome-dependent 
PKR degradation.	Another possibility of a viral protein involved in PKR degradation is the 
protease encoded by MAV-1. The hAd protease is encapsidated in virions and proteolytically 
processes viral proteins IIIa, VI, VII, VIII, mu, and TP (87-90). However, we think it is unlikely 
that the MAV-1 protease degrades PKR, because we showed that UV-inactivated virus was 
unable to degrade PKR. We assume that UV treatment would not destroy the MAV-1 protease 
activity, just as HSV-1 VP16 activity is not altered by UV-inactivation of HSV-1 (91), but we 
have not tested this directly. 	
In summary, we demonstrated that PKR has an antiviral role during MAV-1 infection in 
vitro, because when PKR is mutated, viral replication in MEFs is significantly higher compared 
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to wild type MEFs. Analysis of global PKR steady-state protein levels during infection showed 
complete PKR depletion by 72 hpi in multiple cell types, including immortalized and primary 
cells, with even faster kinetics in some. PKR transcription and translation were not decreased by 
MAV-1 infection, whereas proteasomal inhibition prevented PKR degradation. Taken together, 
these data suggest that MAV-1 causes PKR to be proteasomally degraded at a post-translational 
level. This work provides new insight into possible mechanisms of adenovirus inhibition of PKR 
by DNA viruses. PKR degradation may be induced by other adenoviruses that do not produce 
VA RNA, which includes all animal adenoviruses except primate adenoviruses and one type of 
fowl adenovirus (92).  
 
Materials and Methods 
Cells, mice, virus, and infections 
CMT93 cells (CCL-223) and C57BL/6 MEFs (SCRC-1008) were obtained from the 
American Type Culture Collection and passaged in Dulbecco’s modified eagle media (DMEM) 
containing 5% or 10% heat-inactivated fetal bovine serum (FBS), respectively, before use. 
Primary peritoneal macrophages were obtained from 6-10 week old C57BL/6J mice purchased 
from Jackson Laboratory (#000664) as described (93). Briefly, 6-10 week old C57BL/6J mice 
were injected intraperitoneally with 1.2 mL 3% thioglycolate and euthanized 3-5 days later. The 
abdominal skin was carefully removed, exposing the peritoneum, which was then injected with 5 
mL of sterile phosphate-buffered saline (PBS). The abdomen was massaged gently, then the PBS 
containing the peritoneal macrophages was carefully withdrawn. The macrophages were 
centrifuged at 100 x g for 4 minutes, red blood cells lysed in lysis buffer (0.15 M ammonium 
chloride, 1 mM potassium bicarbonate, and 0.1 mM EDTA disodium salt) for 2 minutes at room 
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temperature, centrifuged at 100 x g for 4 minutes, washed twice in PBS, resuspended in DMEM 
+ 5% heat-inactivated FBS, and plated in 6 well plates. WT and PKR-/- MEFs (termed PKR WT 
MEFs and N-PKR-/- MEFs, respectively, throughout this paper) were obtained from Robert 
Silverman, Cleveland Clinic (94) and were passaged in DMEM containing 10% heat-inactivated 
FBS before use. PKR-/- MEFs stably transfected with empty vector (termed C-PKR-/- MEFs 
throughout this paper), full length human PKR (full length huPKR), kinase dead human PKR 
(kinase-dead huPKR), or RNA binding-deficient human PKR (huPKR) were obtained from Dr. 
Gokhan Hotamisligil, Harvard University (56) and were passaged in DMEM containing 10% 
heat-inactivated FBS before use. WT (SV40-MEFs) and K271R PKR mutant (K271R SV40-
MEFs) MEFs were obtained from Anthony Sadler, Hudson Institute of Medical Research (55) 
and were passaged in DMEM containing 10% heat-inactivated FBS before use. 
N-PKR-/- mice on the C57BL/6J background were obtained from Robert Silverman 
(Cleveland Clinic) (53). The N-PKR-/- mice were bred in-house and both sexes were used in 
experiments. No differences based on sex was noted. All animal work complied with relevant 
federal and University of Michigan policies. Mice were housed in microisolator cages and 
provided with food and water ad libitum. C57BL/6J mice were purchased from Jackson Laboratory 
(#000664). 
Wild type MAV-1 stock was prepared and titrated on mouse NIH 3T6 fibroblasts as 
described previously (95). WT MAV-1 was UV-inactivated by UV-treating 200 µL of virus for 
10 min at 800 mJ/cm2. UV inactivation was confirmed by qPCR and plaque assay. E1A- and E3- 
mutant viruses, pmE109 (69) and pmE314 (72), respectively, have been described previously. 
 For infections, media was removed from cells and adsorption was performed in 0.4 mL of 
inocula for 6-well plate 35-mm wells (unless otherwise noted) for 1 hour at 37˚C. After 60 
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minutes, 2 mL of DMEM+5% FBS was added without removing inocula; this time was 
designated as 0 hpi. For araC experiments, 20 µg/mL araC (Sigma C1768) was added at 0 hpi 
and replenished every 12-16 hours. 
 
Plasmids 
We purchased GFP-epitope tagged ubiquitin plasmids from Addgene (Addgene #11928). 
pmPKR5UTRfullNL contains the 189 nucleotide 5' UTR of mouse PKR (96) (inserted between 
AflII and HindIII restriction sites) upstream of a nanoluciferase gene. The vector containing the 
nanoluciferase gene, AUG-NL-3xFLAG pcDNA3.1, was a gift from the lab of Peter Todd (58). 
pGL4.13 is a standard firefly luciferase plasmid from Promega (Promega E6681). 
 
Immunoblots 
At room temperature, cells were washed once with PBS and PierceTM RIPA lysis buffer 
(Thermo Scientific #89900) with 1x protease inhibitors (Protease Inhibitor Cocktail Kit, Thermo 
Scientific #78410) was added to the plate. The cells were allowed to lyse at room temperature for 
10 minutes before being harvested and centrifuged at 4˚C at 14,000 x g for 10 minutes to remove 
debris. Equivalent amounts of protein, determined by a BCA assay (Pierce BCA Protein Assay 
Kit, Thermo Scientific #23227), were acetone precipitated by incubating with 4x volume ice cold 
acetone overnight at -20˚C. Precipitated proteins were pelleted at 4˚C at 13,000 x g for 10 
minutes and the pellets were dried for 30 minutes at room temperature. Pellets were resuspended 
in 10 µL PierceTM RIPA lysis buffer (Thermo Scientific #89900), 3.25 µL NuPAGE 4x LDS 
Sample Buffer (Invitrogen Cat #NP0007), and 1.25 µL 1M DTT. Samples were incubated at 
37˚C for 10 minutes and then loaded into a well of an 8% acrylamide gel (8.3 cm wide x 7.3 cm 
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high x 0.1 cm thick) with a 2.5% stacking gel, electrophoresed for 30 minutes at 50 V and 85 
minutes at 150 V, and then transferred to a PVDF membrane (BioRad #1620177) for 1 hour at 
100V at 4˚C. Blots were blocked in 5% bovine serum albumin (BSA, Sigma A7906) in tris-
buffered saline (BioRad #1706435) and 0.1% Tween 20 (Sigma P1379). Blots were probed with 
primary antibodies to detect mouse PKR (Santa Cruz D-20 sc-708, 1:2000, or B-10 sc-6282, 
1:200), mouse actin (Santa Cruz sc-1616-R, 1:1000), MAV-1 E1A (AKO-7-147, 1:1000, 
described previously (69)), or MAV-1 late viral proteins (AKO 1-103, 1:1000, described 
previously (97, 98)). Secondary antibodies used were IRDye 800CW anti-rabbit (Li-Cor 925-
32213, 1:15,000) or IgG peroxidase-conjugated anti-mouse (Jackson Immuno 515-035-062, 
1:20,000). Blots were visualized by LI-COR Odyssey imaging (LI-COR Biosciences) or 
enhanced chemiluminescent substrates (Pierce ECL Western Blotting Substrate #32106) and 
X-ray film (Dot Scientific #BDB810). Densitometric quantification was performed on .tif files 
using ImageJ software from NIH (99). 
 
Ubiquitination immunoprecipitations 
To examine PKR ubiquitination status during MAV-1 infection, C57BL/6 MEFs were 
transfected with GFP-epitope tagged ubiquitin plasmids (Addgene #11928) 24 hours before 
infection. We used Polyplus jetPRIME transfection reagent (Polyplus #114-01) with 10 µg 
plasmid DNA and 30 µL jetPRIME reagent per 10 cm plate. At 6 hpi (30 hpt), we treated mock 
and infected C57BL/6 MEFs with 10 µM MG132 (Sigma M7449) for 6 hours before collecting 
lysates at 12 hpi in 300 µL/plate of HCN buffer (50 mM HEPES, 150 mM NaCl, 2 mM CaCl2, 
1% Triton X-100 (Sigma T9284), 1x protease inhibitors (Protease Inhibitor Cocktail Kit, Thermo 
Scientific #78410), and 5 mM N-ethylmalemide). The lysates were split into two aliquots, and 3 
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µg PKR (D-20 sc-708, discontinued) or 3 µg isotype rabbit polyclonal antibody (Jackson 
Immuno #011-000-002) was added to lysates. After rocking samples overnight at 4˚C, 20 µL 
protein A agarose suspension (Calbiochem/Millipore #IP02-1.5ML) was added to each and 
samples were rocked at 4˚C for 2 hours. After incubation, agarose was washed 3 times with 1 
mL HCN buffer, resuspended in 40 µL 2x Laemmli buffer (BioRad #161-0737) with 5% 
2-mercaptoethanol (Sigma M6250), and boiled for 10 minutes. Lysate supernatants remaining 
after the initial PKR immunoprecipitation were then immunoprecipitated again using the same 
procedure but with 4 µg anti-p53 (DO-1, Santa Cruz sc-126) or 4 µg isotype mouse monoclonal 
antibodies (ThermoFisher Scientific #02-6200). Immunoprecipitated proteins were 
immunoblotted for GFP-epitope tagged ubiquitin with antibodies for GFP (1:3,000, Roche 
#11814460001). Blots were also probed for PKR (1:200, PKR B-10 sc-6282), p53 (1:200, anti-
p53 1801 sc-98), ubiquitin (1:1000, ThermoFisher #13-1600), isotype (1:1000, mouse IgG1 
eBioscience 14-4714-82), and IRDye 800CW anti-mouse (Li-Cor 925-32212, 1:15,000) to 
confirm the immunoprecipitations were successful. 
 
Viral yield analysis by qPCR 
Cells were washed twice with room temperature PBS and harvested by scraping into 
PBS, centrifuging at 100 x g for 4 minutes at 4˚C, and resuspending in PBS. Total cellular DNA 
was purified using the Invitrogen PureLink DNA Purification Kit (Thermo Scientific #K1820-
02) and quantitated by a NanoDrop Spectrophotometer. 10 ng of total cellular DNA was 
analyzed by qPCR using custom primers specific to MAV-1 E1A (mE1Agenomic Fwd: 5' GCA 
CTC CAT GGC AGG ATT CT 3' and mE1Agenomic Rev 5' GGT CGA AGC AGA CGG TTC 
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TTC 3') and the results were normalized to GAPDH, which was analyzed using a GAPDH-
specific primer/probe set (ThermoFisher Scientific, Mm99999915_g1, #4331182). 
 
mRNA analysis by qPCR 
Cells were harvested by scraping into media, centrifuging at 100 x g for 4 min at 4˚C, and 
washing the cell pellet three times with ice-cold PBS. RNA was purified using the Qiagen 
RNeasy Mini Kit (Qiagen #74134) and stored at -80˚C. 125 ng of RNA per sample was used to 
make cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems 
#4368814), and 2 µL of the cDNA was analyzed by qPCR using a primer/probe set specific to 
mouse PKR sequence (Thermo Fisher, Mm01235643_m1, #4331182). The results were 
normalized to GAPDH, which was analyzed using a GAPDH-specific primer/probe set 
(ThermoFisher Scientific, Mm99999915_g1, #4331182). Arbitrary units were calculated as 
follows: Mean CT PKR – mean CT GAPDH = DCT for sample. Arbitrary unit = 2^-DCT. 
 
Proteasome inhibition 
C57BL/6 MEFs were infected at an MOI of 10, and DMSO, 1 µM MG132 (Sigma 
M7449), or 1 µM bortezomib (Selleckchem #S1013) were added to the media after a 1 hour 
adsorption. At 24 hpi, cells were washed once with room temperature PBS, and PierceTM RIPA 
lysis buffer (Thermo Scientific #89900) with 1x protease inhibitors (Protease Inhibitor Cocktail 
Kit, Thermo Scientific #78410) was added to the plate. The cells were allowed to lyse at room 
temperature for 10 minutes before being harvested and centrifuged at 4˚C at 14,000 x g for 10 
minutes to remove debris.   
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Lysosome inhibition and DQ BSA assay 
CMT93 cells were infected at an MOI of 10. After a 1 hour adsorption, 10 µL water, 10 
mM NH4Cl (final concentration, Baker Chemical Company #0660-1), or 60 µM chloroquine 
(final concentration, Sigma C6628) was added to the media. At 24 hpi, at room temperature, 
cells were washed once with PBS and PierceTM RIPA lysis buffer (Thermo Scientific #89900) 
with 1x protease inhibitors (Protease Inhibitor Cocktail Kit, Thermo Scientific #78410) was 
added to the plate. The cells were allowed to lyse at room temperature for 10 minutes before 
being harvested and centrifuged at 4˚C at 14,000 x g for 10 minutes to remove debris.  
The DQ BSA assay was performed as described (61). Briefly, C57BL/6 MEFs and 
CMT93 cells were plated at 1.5 x 105 cells/plate or 3 x 105 cells/plate, respectively, in MatTek 
Glass Bottom Microwell Dishes (Part No: P35G-1.5-14C) with 2 mL of DMEM + 10% or 5% 
FBS, respectively. The next day, the cell media was treated with 10 µL water, 10 mM NH4Cl 
(final concentration), or 60 µM chloroquine (final concentration, Sigma C6628). Four hours after 
adding inhibitors, DQ Red BSA (Invitrogen Cat #D12051) was added to the media to a final 
concentration of 5 µg/mL in 2 mL DMEM + 10% or 5% FBS, respectively. At 24 hours post 
treatment, the cells were imaged on a Nikon TE300 inverted microscope equipped with a 
mercury arc lamp, Plan-Apochromat 60x, 1.4 NA objective, cooled digital CCD camera (Quantix 
Photometrics, Tucson, AZ), and a temperature-controlled stage, set at 37˚C. To image the DQ-
BSA, we used an excitation filter centered at 572 nm and an emission filter centered at 635 nm. 
The exposure time was the same for all images. 
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Ribosome pelleting 
Ribosomes were pelleted as described (100). Briefly, C57BL/6 MEFs were plated on 10 
cm plates, 3x105 cells per plate. The next day, the cells (~90% confluent) were infected with 
MAV-1 at an MOI of 5. C57BL/6 MEF lysates were collected at 48 hpi by scraping the cells in 
ice-cold PBS containing 100 µg/mL cycloheximide (Sigma C7698), pelleting, and resuspending 
in lysis buffer, which was 10 mM HEPES pH 7.5, 100 mM KCl, 5 mM MgCl2, 4 mM DTT, 
0.5% NP-40, 100 µg/mL cycloheximide, 20 U/mL RNasin (Promega #	N2511), 10% sucrose, 
and 1x protease inhibitors (Protease Inhibitor Cocktail Kit, Thermo Scientific #78410). Cells 
were lysed by passage through a chilled 26G needle five times and cleared by centrifugation for 
10 min at 21,000 x g at 4˚C. 400 µL of cleared lysate (10 OD260nm units) was layered onto 25% 
sucrose and centrifuged 29,500 rpm in an SW41 rotor (107,458 rcf average) for 4 hours at 4˚C. 
After pelleting, the supernatant was removed with a micropipet and 350 µL of 4˚C Buffer RLT 
Plus (from Qiagen RNeasy Mini Kit) was added to the pellet to collect the RNA. RNA was 
purified immediately using the Qiagen RNeasy Mini Kit (Qiagen #74134) and stored at -80˚C 
until analysis. 
 
Polyribosome gradients 
C57BL/6 MEFs were plated on 10 cm plates, 2 x 106 cells per plate. The next day, the 
cells were infected with MAV-1 at an MOI of 2. Following a standard protocol (101), 5 minutes 
prior to collection, cycloheximide was added at a final concentration of 100 µg/mL and 
incubated at 37˚C. Cells were collected at 24 hpi by scraping in ice-cold PBS containing 100 
µg/mL cycloheximide, pelleting, and resuspending in 500 µL lysis buffer (20 mM Tris-Cl, 150 
mM NaCl, 15 mM MgCl2, 8% glycerol, 20 IU/mL SUPERase•In (ThermoFisher Scientific Cat# 
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AM2696), 80 IU/mL Murine RNAse Inhibitor (New England BioLabs Cat# M0314S), 0.1 
mg/mL heparin (Sigma H3393-50), 0.1mg/mL cycloheximide, 1 mM DTT, 1x protease inhibitor 
(Protease Inhibitor Cocktail Kit, Thermo Scientific #78410), 20 IU/mL Turbo DNAse 
(ThermoFisher Scientific Cat# AM2238), and 1% Triton X-100 (Sigma T9284). Cells were lysed 
by passaging through a chilled 26G needle ten times, vortexing for 30 seconds, and then 
incubating on ice for 5 min. Lysates were cleared by centrifugation for 5 min at 14,000 x g at 
4˚C. 500 µL of cleared lysate (10 OD260nm) was layered onto a 10-50% sucrose gradient and 
centrifuged at 35,000 rpm in an SW41 rotor (151,000 rcf) for 3 hours at 4˚C. After 
centrifugation, gradients were pumped out of the top with a Brandel BR-188 Density Gradient 
Fractionation System with a continuous reading of the OD254 nm. From 24-34 fractions (350-500 
µL) were collected. RNA was purified from selected fractions immediately using the Qiagen 
RNeasy Mini Kit (Qiagen #74134) and stored at -80˚C until analysis by RT-qPCR. 
 
Nanoluciferase assays 
For both CMT93 cells and C57BL/6 MEFs, approximately 7500 cells were seeded into 
each well of a 96-well plate. The following day, the cells were co-transfected with 
pmPKR5UTRfullNL and pGL4.13 using jetPRIME reagent (Polyplus 114-01) using the standard 
Polyplus protocol, with 200 ng total of plasmid and 0.6 µL of jetPRIME reagent per well. 24 
hours after transfection, the cells were infected with MAV-1 at an MOI of 10. 24 hours after 
infection (48 hpt), cells were lysed in 70 µL/well Glo Lysis buffer (Promega E2661). 25 µL of 
each lysed sample was added to each of two wells of a black 96-well plate (Greiner Microlon 
black microplate, Fisher Scientific #07-000-634). To each sample, we added either 25 µL of 
OneGlo (Promega E6110) or 25 µL NanoGlo (Promega N1110). After 5 minutes, the plate was 
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read on a Promega Glomax luminometer. Each NanoGlo reading (from pmPKR5UTRfullNL) 
was normalized to its corresponding OneGlo reading (from pGL4.13).  
 
Statistical analyses 
Data were analyzed with GraphPad Prism 7.0 software. For qPCR and densitometry 
analyses, the data were analyzed by individual Mann-Whitney tests. A value of P < 0.5 was 
considered significant.  
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Chapter III 
Changes in immune response in GCN2-/- mice and macrophages during mouse adenovirus 
type 1 infection 
 
Abstract 
During viral infection, the production of double-stranded (ds) RNA by viruses triggers 
protein kinase R (PKR) activation and subsequent eukaryotic translation initiation factor 2a 
(eIF2a) phosphorylation, reducing cellular translation, and viral translation and replication. This 
antiviral host response, resulting in eIF2a kinase phosphorylation, may also occur with the other 
three eIF2a-phosphorylating kinases (general control nonderepressible 2 [GCN2], PKR-like 
endoplasmic reticulum kinase, and heme-regulated inhibitor kinase), resulting in protein 
synthesis inhibition in response to viral infection. GCN2 phosphorylates eIF2a in response to 
amino acid starvation, UV irradiation, and oxidative stress. Several viruses indirectly or directly 
cause GCN2 activation during infection. Here we describe that GCN2-/- deficient (atchoum or 
atc) mice and peritoneal macrophages are significantly more susceptible to infection by mouse 
adenovirus type 1 (MAV-1). Viral yield assays of infected organs showed that only the cecum of 
atc mice at 8 days post infection (dpi) had significantly higher viral yields than infected organs 
from wild type mice, indicating that the difference in survival between atc and wild type mice is 
not likely a result of increased viremia in atc mice. There was also no significant difference in 
histology of organs from MAV-1-infected atc and wild type mice. However, cytokine analysis 
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showed that MAV-1-infected wild type mice had significantly higher levels of interleukin 1a 
(IL-1a), interleukin 1b (IL-1b), tumor necrosis factor a (TNFa), interleukin 6 (IL-6), and 
interferon g (IFNg) in the brain compared to infected atc mouse brains at 8 dpi, suggesting that a 
difference in inflammatory response could be responsible for the decreased survival of atc mice 
in response to MAV-1 infection. 
 
Introduction 
One host response to viral infection is to reduce global cellular translation through eIF2a 
phosphorylation, reducing viral translation and viral replication (1-4). As discussed in the 
introduction to Chapter II, PKR is the canonical eIF2a kinase that is activated during viral 
infection by dsRNA (5-7). However, many viruses encode proteins that inhibit PKR activation or 
block its activity (8). In response to this viral circumvention of the host PKR response, it is 
possible that the host cell also recruits one of the other three eIF2a-phosphorylating kinases 
(GCN2, PKR-like endoplasmic reticulum kinase, and heme-regulated inhibitor kinase) to inhibit 
protein synthesis in response to viral infection (9-11).  
GCN2 is comprised of four main domains: an eIF2a kinase domain, a histidyl-tRNA 
synthetase (HisRS)-like domain, a general control of amino-acid synthesis 1 (GCN1) binding 
domain, and a ribosomal binding domain (Fig. 3.1) (11-15). GCN2 first binds to ribosomes, and 
then uncharged tRNAs bind to the HisRS-like domain and cause a conformational change that 
causes GCN2 activation (16-21). GCN1 is an activator of GCN2; it binds to ribosomes, and 
assists in the transfer of uncharged tRNA to GCN2 (16). GCN2 phosphorylates eIF2a in 
response to amino acid starvation, UV irradiation, and oxidative stress; in yeast, GCN1 is 
required for GCN2 activation in each of these responses (16).  
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Figure 3.1 GCN2 (Eif2ak4) domains, adapted from Figure 1B from Jaspart et al. GCN2 contains four major 
domains: RING finger-containing proteins, WD-repeat-containing proteins, and yeast DEAD (DEXD)-like 
helicases (RWD) binding domain; kinase domain; histidyl-tRNA synthetase (HisRS)-like domain; and the 
ribosome binding/homodimerization domain (RB/DD). GCN2 binds to GCN1 using the GCN2 RWD 
domain; uncharged tRNA binds using the HisRS-like domain; and the ribosome binds to the RB domain. 
GCN2 homodimerizes using the RB/DD domain.
RWD domain Kinase domain HisRS-like domain
RB/DD domain
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GCN2-/- (atchoum or atc) mice were created using N-ethyl-N-nitrosourea-mutagenesis of 
mice on a C57BL/6 background (22). When infected with mouse cytomegalovirus (MCMV) or a 
human adenovirus reporter construct, peritoneal macrophages from the atc mice have increased 
susceptibility to both viruses compared to wild type mouse peritoneal macrophages. 
Additionally, atc mice infected with MCMV have a significantly lower survival rate than wild 
type mice. Genome sequencing showed that the atc mice have a missense mutation (T to C 
transition) in exon 2 of the Eif2ak4 gene, which causes exon skipping. Eif2ak4 encodes GCN2. 
In atc macrophages, GCN2 is not detectable by immunoblotting, and in atc mouse embryonic 
fibroblasts (MEFs), phosphorylation of eIF2a does not occur in response to UVB treatment or 
MCMV infection. Thus atc is a loss-of-function mutation with respect to eIF2a phosphorylation.  
While there is much research implicating PKR in the innate immune response to a wide 
range of viruses, the fact that atc mice are more susceptible to MCMV infection supports 
findings that GCN2 may play a role in the innate immune response to viruses (22). Two viruses, 
MCMV (23) and yellow fever virus vaccine (YF-17D) (24), indirectly activate GCN2 by 
triggering changes in amino acid metabolism. MCMV infection leads to the production of 
25-hydroxycholesterol, which activates GCN2 by reducing the levels of intracellular cysteine 
and/or by generating oxidative stress (23). YF-17D has much the same effect. After incubation 
with YF-17D, dendritic cells have a significant reduction in levels of free arginine and a 
subsequent increase in phosphorylated GCN2 and eIF2a (24). 
Other viruses, however, trigger GCN2 activation directly through the production of RNA, 
such as Sindbis virus (25) and HIV-1 (26). Both viruses produce RNA that binds to the 
HisRS-like domain of GCN2, leading to activation. The prunnus necrotic ringspot virus, a plant 
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virus, causes GCN2 activation through the production of a viral movement protein, though the 
mechanism of activation is not known (27).  
To oppose the effect of GCN2 activation on cellular translation, several viruses also have 
mechanisms for inhibiting GCN2 activation or activity. Herpes simplex virus 1 indirectly inhibits 
GCN2 by targeting GCN1 (28, 29). Herpes simplex virus 1 glycoprotein H directly interacts with 
GCN1, changing its localization from the cytoplasm to the nuclear rim, effectively sequestering 
GCN1 and inhibiting its ability to activate GCN2 during infection. Severe acute respiratory 
syndrome-related coronavirus also indirectly inhibits GCN2. It does so by causing a depletion of 
GCN2 protein from the cell late in infection, likely by decreasing host gene transcription overall 
(30). Vaccinia virus and HIV-1 have more direct mechanisms of GCN2 inhibition. The vaccinia 
virus K3L protein inactivates GCN2 by binding to the kinase domain and preventing GCN2 
activation (31). HIV-1pro, a protease produced by HIV-1, cleaves GCN2, and once GCN2 is 
cleaved, it loses nearly all of its capability to phosphorylate eIF2a (26). 
To determine whether GCN2 plays an antiviral role during MAV-1 infection, we infected 
atc and wild type mice for survival studies. At three different doses, atc mice had a significantly 
lower survival rate compared to wild type mice. Peritoneal macrophages from atc mice infected 
with MAV-1 also had increased viral yields compared to peritoneal macrophages from wild type 
mice. However, there was no difference in viral yields between MAV-1-infected atc MEFs 
compared to wild type MEFs. Viral yield determinations from infected mouse organs showed 
that only the cecum of atc mice at 8 dpi had higher viral yields than cecum from wild type mice. 
This result suggests that the difference in survival between atc and wild type mice was not a 
result of increased viremia in atc mice. There was also no significant difference in the histology 
of organs from MAV-1-infected atc and wild type mice. However, cytokine analysis showed a 
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difference in IL-1a, IL-1b, TNFa, IL-6, and IFNg levels in the brains of atc and wild type mice 
at 7 and 8 dpi, suggesting that a difference in inflammatory response could be responsible for the 
decreased survival of atc mice in response to MAV-1 infection. 
 
Results 
Atc mice are more susceptible to infection by MAV-1 than wild type mice  
To determine whether GCN2-deficient mice are more susceptible to MAV-1 infection, 
we infected atc and C57BL/6 (wild type) mice intraperitoneally (i.p.) with 102, 103, or 104 PFU 
MAV-1 and recorded survival for 21 dpi. At all three doses, atc mice had a significantly lower 
survival than wild type mice, with their survival being 24%, 41%, and 40% lower than the 
survival of the wild type mice, respectively (Fig. 3.2). These results indicate that GCN2 plays a 
role in the survival of mice infected with MAV-1. 
 
Viral yield is increased in atc peritoneal macrophages 
To further characterize the role GCN2 plays during MAV-1 infection, peritoneal 
macrophages or immortalized MEFs isolated from atc and wild type mice were plated and 
infected with MAV-1 at MOI of 1, and cells were collected at 24, 48, and 72 hpi. DNA was 
purified from the cell pellets and analyzed for MAV-1 genome copies by qPCR. At 72 hpi, the 
atc macrophages had a more than three-fold increase in viral yield compared to the wild type 
macrophages (Fig. 3.3A). These results correlate with the results of the survival studies and 
suggest that GCN2 is antiviral in MAV-1-infected peritoneal macrophages. However, in atc and 
wild type MEFs infected with MAV-1 at MOI of 1, the atc MEFs had lower viral yields  
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Figure 3.2 Atc mutation reduces survival of MAV-1-infected mice. Wild type mice (C57BL/6) and GCN2-/-
mice (atc) were infected intraperitoneally with (A) 102, (B) 103, or (C) 104 pfu MAV-1, and survival was 
recorded for 21 days. *P ≤ 0.05. The data shown are pooled from independent experiments. The number of 
mice in each group is listed next to the line label.
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Figure 3.3 Viral yield in wild type and GCN2-/- primary macrophages and MEFs. (A) Wild type (C57BL/6) 
and GCN2-/- (atc) macrophages or (B) MEFs were infected with MAV-1 at an MOI of 1 and collected at 24, 
48, and 72 hours post infection (hpi), as well as 96 hpi for MEFs. DNA was purified from cell pellets and 
analyzed for MAV-1 genome copies by qPCR. Graphs are representative of multiple experiments, 6-18 
biological replicates per cell line per time point. Error bars are standard error of the mean (SEM). *P ≤ 0.05, 
**P ≤ 0.01
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compared to wild type MEFs (Fig. 3.3B). This is consistent with the results of MCMV infection 
in atc mice, peritoneal macrophages, and MEFs, where atc mice and macrophages are more 
susceptible to MCMV infection, but atc MEFs are not (22). Taken together, these data suggest 
that the antiviral role of GCN2 may vary based on cell type for both MAV-1 and MCMV. 
 
Atchoum mice only have significantly higher viral titers in the cecum during infection 
MAV-1 is an encephalitic virus, so we quantitated viral loads in the brains of 
MAV-1-infected atc and wild type mice. Mice were infected i.p. with 103 PFU MAV-1 and 
brains were harvested at 3, 5, and 7 dpi. DNA was purified from homogenized tissue samples 
and analyzed for MAV-1 genome copies by qPCR. There was no significant difference between 
the viral loads in the brains of atc mice compared to wild type mice at any of the analyzed time 
points (Fig. 3.4A). To determine if any other organ in the atc mice was more susceptible to 
MAV-1 than wild type mice, we quantitated the viral loads at 5 and 7 dpi in the liver, lung, heart, 
spleen, kidney, and cecum of atc and wild type mice infected i.p. with 103 PFU MAV-1. There 
was no significant difference in the viral load in any organ between the atc and wild type mice at 
either time point except for the cecum at 7 dpi (Fig. 3.4B and C). Higher viral yields in the 
cecum could indicate a gastrointestinal component to the increased mortality of atc mice during 
MAV-1 infection. However, histology analysis of the cecum and all other organs showed no 
significant differences in inflammation or damage between atc organs and wild type organs. We 
also analyzed a portion of the brains and livers for infectious virus by plaque assay, and there 
were no differences in infectious titers from the brains or livers of MAV-1-infected wild type or 
atc mice (Fig. 3.5). Taken together, these results suggest that the increased mortality seen in atc  
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Figure 3.4 Viral load is increased in the cecum of GCN2-/- (atc) mice. (A) Wild type (C57BL/6) and GCN2-/-
(atc) mice were infected with MAV-1 at 103 pfu. After 3, 5, or 7 days post infection, mice were euthanized 
with CO2, perfused with phosphate-buffered saline, and organs were collected. DNA was purified from (A) 
brain tissue at 3, 5, and 7 days post infection or heart, lung, liver, spleen, kidney, and cecum at (B) 5 days 
post infection or (C) 7 days post infection. DNA was analyzed for MAV-1 genome copies by qPCR. Graph is 
representative of multiple experiments; each dot represents a different mouse. Error bars are standard error 
of the mean (SEM). *P ≤ 0.05.
Compiled Data Brain Viral Load
3 5 7
100
102
104
106
108
1010
Days post infection
M
AV
-1
 G
en
om
e 
C
op
ie
s/
5 
ng
 D
N
A
C57BL/6
atc
3 dpi: N = 5 for B6 and 4 for Atc
5 dpi: N = 10 for B6 and 11 for Atc
7 dpi: N = 11 for B6 and 12 for Atc
heart lung liver spleen kidney cecum
101
102
103
104
105
106
107
Organ
M
AV
-1
 G
en
om
e 
C
op
ie
s/
5 
ng
 D
N
A
Graph by Organ 5 dpi w/o brain
C57BL/6
atc
heart lung liver spleen kidney cecum
101
102
103
104
105
106
107
Organ
M
AV
-1
 G
en
om
e 
C
op
ie
s/
5 
ng
 D
N
A
Graph by Organ 7 dpi w/o brain
C57BL/6
atc
*
	 99 
 
 
 
 
B
C
Figure 3.5 Comparison of infectious virus and viral DNA yields in brains and livers of MAV-1-infected wild 
type and GCN2-/- mice. Wild type (C57BL/6) and GCN2-/- (Atchoum) mice were infected with MAV-1 at 103
pfu. After 7 days, mice were euthanized with CO2, perfused with phosphate-buffered saline, and organs were 
collected. (A) Brains and livers were homogenized and infectious virus was titrated by plaque assay on 3T6 
cells. DNAs purified from (B) brains and (C) livers were analyzed for MAV-1 genome copies by qPCR and 
compared to the infectious viral titers. Each symbol represents an individual mouse. There were no statistical 
differences between mouse strains for titers or viral DNA yield. 
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mice compared to wild type mice was not due to increased viral replication or inflammatory 
damage. 
 
MAV-1-infected atc mice have a different inflammatory cytokine response than wild type 
mice in the brain 
During infection, cytokines and chemokines can be secreted in the brain by resident cells 
or by infiltrating inflammatory cells (32). IL-1a, IL-1b, IL-6, and TNFa are proinflammatory 
cytokines that are secreted by resident CNS cells and macrophages found in the brain (33), while 
monocyte chemoattractant protein-1 (MCP-1) and KC are secreted in response to the 
proinflammatory cytokines (34, 35). IL-1b and TNFa specifically enhance encephalitis during 
rabies infections in rats (36). However, mice deficient in IL-1 signaling have reduced survival 
during MAV-1 infection compared to wild type mice, suggesting that the IL-1 signaling pathway 
has a protective role during MAV-1 infection specifically (37). We analyzed cytokine levels in 
the brains of MAV-1-infected or mock infected atc and wild type mice. Mice were infected i.p. 
with 103 PFU MAV-1, and brains were harvested at 7 and 8 dpi. Brain extracts were analyzed by 
ELISA for IL-1a, IL-1b, IL-6, IL-10, interferon g-induced protein 10 (IP-10), TNFa, IFNg, KC, 
MCP-1, and RANTES (cytokines that were previously shown to be elevated in wild type mouse 
brains during MAV-1 infection (37)).  
At 7 dpi, IL-1a, IL-1b, and IFNg levels (normalized to the corresponding mock levels) 
were significantly higher in MAV-1-infected atc brains compared to wild type brains. In 
contrast, at 8 dpi, IL-1a, IL-6, TNFa, KC, and MCP-1 levels (normalized to the corresponding 
mock levels) were significantly lower in MAV-1-infected atc brains compared to wild type (Fig. 
3.6). These results suggest that atc mice may have an earlier inflammatory response in the brain  
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Cytokine dpi
Mean cytokine levels 
in infected C57BL/6 
brains (pg/mL)
Mean cytokine 
levels in infected 
atc brains (pg/mL)
IL-1a
7 43.1 44.8
8 39.0a 29.0
IL-1b
7 62.5 62.5
8 90.4a 75.8
IL-6
7 33.3 32.3
8 26.1b 16.2
IL-10
7 24.3 21.1
8 56.5 50.4
IP-10
7 2474.8 2835.4
8 3873.6 2634.5
TNFa
7 12.9 10.9
8 30.5b 21.5
IFN! 7 18.9 17.6
8 23.6 21.9
KC
7 170.5 182.8
8 138.5a 77.4
MCP-1
7 488.0 384.5
8 601.5a 152.0
RANTES
7 207.1 235.9
8 248.1 186.3
Table 3.1 Reduced cytokine levels in MAV-1-infected atc mouse brains compared to 
C57BL/6 mouse brains.
a P ≤ 0.05
b P ≤ 0.01
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Figure 3.6 Changes in cytokine levels between MAV-1-infected atchoum and wild type mouse brains. 
GCN2-/- (Atchoum) and wild type (C57BL/6) mice were infected i.p. with 103 PFU MAV-1 or mock infected 
and brains were harvested at 7 and 8 dpi. Brain extracts were prepared in a 10% weight/volume PBS and 
analyzed by ELISA for IL-1a, IL-1b, IFN- g, MCP-1, KC, and TNFa. Each dot represents a different mouse. 
Horizontal bar represents the mean. *P ≤ 0.05, **P ≤ 0.01, **P ≤ 0.001.
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than wild type mice. At 8 dpi, wild type mice also had higher absolute levels of IL-1a, IL-1b, 
IL-6, TNFa, KC, and MCP-1 than atc mice (Table 3.1). The differences in cytokine and 
chemokine responses to MAV-1 infection between atc and wild type mouse brains suggest that 
the immune cells that produce these cytokine and chemokines may have different levels of 
activity or localization in the presence of GCN2.  
 
Discussion 
 We have characterized the atc phenotype during MAV-1 infection. GCN2-/- mice and 
primary peritoneal macrophages were more susceptible to MAV-1 infection compared to wild 
type mice and macrophages, but GCN2-/- MEFs were not (Fig. 3.2 and 3.3). The lower survival 
of GCN2-/- mice compared to wild type mice was not explained by increased viremia or tissue 
damage, because there was no difference in viral yields or histology between any organs assayed 
from MAV-1-infected GCN2-/- or wild type mice except for the cecum (Fig. 3.4). However, there 
were differences in pro-inflammatory cytokine and chemokine responses to MAV-1 infection in 
the brains of GCN2-/- and wild type mice. Normalized levels of IL-1a, IL-1b, and IFNg were 
significantly higher in MAV-1-infected atc brains compared to wild type brains at 7 dpi, while 
normalized levels of IL-1a, IL-6, TNFa, KC, and MCP-1 levels were significantly lower in 
MAV-1-infected atc brains compared to wild type at 8 dpi (Fig. 3.6). This suggests that the 
cytokine response in the atc brains peaks earlier during infection than the cytokine response in 
wild type mice. This early peak at 7 dpi and drop in cytokines at 8 dpi may explain why the atc 
mouse survival decreases significantly after 7 dpi compared to the survival of the wild type mice 
(Fig. 3.2). 
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Compared to wild type cells, the higher viral yield in GCN2-/- macrophages, similar viral 
yields in GCN2-/- MEFs, and the differences in brain cytokine levels during infection between 
mice of each strain suggest that the GCN2-/- mice may mount a different immune response to 
MAV-1 infection than wild type mice, specifically in immune cells. Other viruses serve as 
precedents for this. YF-17D infection of GCN2-/- mice and dendritic cells results in decreased 
immune response (24). In GCN2-/- dendritic cells incubated with YF-17D, autophagy is reduced 
compared to wild type dendritic cells. Autophagy in dendritic cells is critical for proper antigen 
cross-presentation during infection, and consequently GCN2-/- mice immunized with YF-17D 
also have reduced proliferation of CD8+ and CD4+ YF-17D-specific T-cells compared to control 
mice. This suggests that GCN2 plays a role in promoting antigen cross-presentation and priming 
secondary immunity during YF-17D immunization. Assaying MAV-1-infected GCN2-/- dendritic 
cells for levels of autophagy markers would show whether autophagy is similarly impaired, and 
measuring CD8+ and CD4+ specific T-cells in the organs of GCN2-/- mice infected with MAV-1 
would give additional insight into the immune response mounted by GCN2-/- mice during 
MAV-1 infection. 
In summary, we have shown that GCN2-/- mice and primary peritoneal macrophages were 
more susceptible to MAV-1 infection than wild type mice, indicating that GCN2 is antiviral 
during MAV-1 infection. However, we have been unable to demonstrate GCN2 activation 
(phosphorylation) during MAV-1 infection due to the unavailability of good antibodies to mouse 
GCN2 (Goodman and Spindler, unpublished). The reduced survival of GCN2-/- mice is not likely 
to be due to increased viremia or extensive inflammatory damage in any organs, because the 
viral loads and histology in GCN2-/- mouse organs were similar those in wild type mouse organs 
except for the cecum. This difference seen in the cecum could be investigated more thoroughly 
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to determine if GCN2 plays an antiviral role in the gut. However, there was a difference in 
inflammatory cytokine response in MAV-1-infected GCN2-/- mouse brains compared to wild 
type mouse brains, suggesting that the differences in survival could stem from a difference in the 
immune response in the brain. GCN2-/- primary macrophages produced more MAV-1 genome 
replication compared to wild type primary macrophages. However, this was not seen in MEFs, 
where higher yields occurred for wild type cells than GCN2-/- cells (Fig. 3.3B). Similar results 
were seen in GCN2-/- macrophages and MEFs when compared to wild type MEFs when infected 
with MCMV (22). This suggests that the effects of GCN2 are cell-type specific. Assaying the 
responses from specific immune cells, including GCN2-/- dendritic cells, macrophages, and 
T-cells, could help to further characterize the differences in immune response between GCN2-/- 
and wild type animals. 
 
Materials and methods 
Virus, mice, and cells 
Wild type MAV-1 stock was prepared and titrated on mouse NIH 3T6 fibroblasts as 
described previously (38).  
Atc mice on the C57BL/6J background were obtained from Bruce Beutler (UT 
Southwestern Medical Center) (22). The atc mice were bred in-house and both sexes were used 
in experiments. Atc mutation was confirmed by genotyping mice as described below. No 
differences based on sex was noted. All animal work complied with relevant federal and 
University of Michigan policies. Mice were housed in microisolator cages and provided food and 
water ad libitum. C57BL/6J mice were purchased from Jackson Laboratory (#000664). 
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C57BL/6 MEFs (SCRC-1008) were obtained from the American Type Culture Collection 
and passaged in Dulbecco’s modified eagle media (DMEM) containing 10% heat-inactivated 
fetal bovine serum (FBS) before use. Atc MEFs were obtained from 13-16 day old embryos 
(estimated) using previously described methods (39). Briefly, a pregnant atc mouse was 
euthanized by CO2 asphyxiation and the embryos were removed from the uterus and placed in a 
sterile petri dish. The heads and viscera were removed from the embryos and the remaining 
tissue was minced up and trypsinized with 0.25% trypsin/EDTA for 15 minutes. Cells were 
seeded at a density of one embryo/175 cm2 tissue culture treated flask in DMEM + 10% FBS and 
incubated at 37˚C with 5% CO2 for three to four days. When the flasks became confluent, the 
cells were split into 10 cm plates. 
Atc MEFs were immortalized using a modified 3T3 immortalization protocol (40). 
Briefly, a frozen aliquot of non-immortalized atc MEFs at passage 2 was thawed and plated on a 
100 mm plate (day 1) in DMEM containing 10% heat-inactivated FBS. On day 4, the MEFs were 
trypsinized, counted on a hemocytometer, and 3.5 x 105 cells were plated on 60 mm plates; all 
cells were plated. This step was repeated every 3 days. Cell numbers decreased between passage 
6-10, and cells started to show signs of immortalization around passage 15-20. After consistent 
cell number increases for several passages, cells were transitioned to 100 mm plates and 
genotyped as described below to confirm that the atc mutation was maintained. 
Primary peritoneal macrophages were obtained from 6-10 week old atc mice, or 
C57BL/6J mice purchased from Jackson Laboratory (#000664) as described (41). Briefly, 6-10 
week old C57BL/6 mice were injected intraperitoneally with 1.2 mL 3% aged thioglycollate and 
euthanized 3-5 days later. The abdominal skin was carefully removed, exposing the peritoneum, 
which was then injected with 5 mL of sterile phosphate-buffered saline (PBS). The abdomen was 
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massaged gently, then the PBS containing the peritoneal cells was carefully withdrawn. The cells 
were centrifuged at 100 x g for 4 minutes, red blood cells lysed in lysis buffer (0.15 M 
ammonium chloride, 1 mM potassium bicarbonate, and 0.1 mM EDTA disodium salt) for 2 
minutes at room temperature. The macrophage cells were centrifuged at 100 x g for 4 minutes, 
washed twice in PBS, resuspended in DMEM + 5% heat-inactivated FBS, and plated in 6 well 
plates. 
 
Genotyping for GCN2 mutation 
 DNA from mouse tails was obtained as described (42). DNA from immortalized MEFs 
was purified using Invitrogen PureLink DNA Purification Kit (Thermo Scientific #K1820-02) 
and PCR amplified the mutation region using primers Eif2ak4atc F: 5'-AAT TGG CTG GGA 
CGG TGT CAA G-3' and Eif2ak4atc R – 5'-GGA AGC ACT TTA AAT GCT CGC CAC-3' 
(22). The PCR was cleaned up with the Qiagen PCR Clean up kit and submitted for sequencing 
using the Eif2ak4atc F primer to the University of Michigan DNA Sequencing Core. 
 
Immunoblots (Information for Fig. 4.2) 
At room temperature, cells were washed once with PBS and PierceTM RIPA lysis buffer 
(Thermo Scientific #89900) with 1x protease inhibitors (Protease Inhibitor Cocktail Kit, Thermo 
Scientific #78410) was added to the plate. The cells were allowed to lyse at room temperature for 
10 minutes before being harvested and centrifuged at 4˚C at 14,000 x g for 10 minutes to remove 
debris. Equivalent amounts of protein, determined by a BCA assay (Pierce BCA Protein Assay 
Kit, Thermo Scientific #23227), were acetone precipitated by incubating with 4x volume ice cold 
acetone overnight at -20˚C. Precipitated proteins were pelleted at 4˚C at 13,000 x g for 10 
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minutes and the pellets were dried for 30 minutes at room temperature. Pellets were resuspended 
in 10 µL PierceTM RIPA lysis buffer (Thermo Scientific #89900), 3.25 µL NuPAGE 4x LDS 
Sample Buffer (Invitrogen Cat #NP0007), and 1.25 µL 1M DTT. Samples were incubated at 
37˚C for 10 minutes and then loaded into a well of an 8% acrylamide gel (8.3 cm wide x 7.3 cm 
high x 0.1 cm thick) with a 2.5% stacking gel, electrophoresed for 30 minutes at 50 V and 85 
minutes at 150 V, and then transferred to a PVDF membrane (BioRad #1620177) for 1 hour at 
100V at 4˚C. Blots were blocked in 5% bovine serum albumin (BSA, Sigma A7906) in tris-
buffered saline (BioRad #1706435) and 0.1% Tween 20 (Sigma P1379). Blots were probed with 
primary antibodies to detect mouse p-eIF2a (Invitrogen #44728G, 1:2000), eIF2a (Invitrogen 
#AHO1182, 1:500), and actin (Santa Cruz sc-1616-R, 1:1000). The secondary antibody used was 
IgG peroxidase-conjugated anti-rabbit (Thermo Scientific #31462, 1:30,000). Blots were 
visualized by enhanced chemiluminescent substrates (Pierce ECL Western Blotting Substrate 
#32106) and X-ray film (Dot Scientific #BDB810). Densitometric quantification was performed 
on .tif files using ImageJ software from NIH (43). 
 
Mouse infections  
Mice 4-5 weeks old were infected via i.p. injection with 102, 103, or 104 PFU in a volume 
of 100 µL. Virus was diluted in 10-fold serial dilutions in endotoxin-free Dulbecco’s phosphate-
buffered saline (DPBS; Gibco 14190-144). Mock infected mice were injected with conditioned 
media diluted similarly in DPBS. Mice were monitored twice daily for signs of disease (e.g., 
ruffled fur, hunched posture, seizures, inability to feed) and were euthanized by CO2 
asphyxiation if moribund or at the indicated time points. Organs were harvested, snap frozen on 
dry ice, and stored at -20˚C or -70˚C until processed. 
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Quantitating viral yield by qPCR from cells and tissue 
DNA for measurement of viral load was extracted from 20 mg of organ tissue or cells 
using the Invitrogen PureLink DNA Purification Kit (Thermo Scientific #K1820-02) and 
quantitated by a NanoDrop Spectrophotometer. 5 ng of total DNA for organ tissue or 2 µL of 
purified cellular DNA was analyzed by qPCR using custom primers specific to MAV-1 E1A 
(mE1Agenomic Fwd: 5' GCA CTC CAT GGC AGG ATT CT 3' and mE1Agenomic Rev 5' GGT 
CGA AGC AGA CGG TTC TTC 3'), and the results were either normalized to GAPDH (Fig. 
3.3), which was analyzed using a GAPDH-specific primer/probe set (ThermoFisher Scientific, 
Mm99999915_g1, #4331182) or compared to a standard curve of mE1A (Fig. 3.4). Results 
normalized to GAPDH (DDCT) were also normalized to mock at 24 hpi (Fig. 3.3). Each sample 
was assayed in triplicate. 
 
Mouse brain and liver plaque assays 
  90-110 mg of brain or liver tissue were prepared in a 10% weight/volume solution with 
PBS by adding the tissue and corresponding amount of PBS to bead beater tubes. They were then 
homogenized with sterile glass beads in a mini Beadbeater (Biospec Products) three times for 1 
minute, with a 1 minute rest on ice between each homogenization. The tubes were put through 3 
freeze/thaw cycles and then centrifuged at 2000 x g for 5 minutes at 4˚C to remove the remaining 
tissue debris. The supernatant was transferred to a new tube. The supernatants were then 
analyzed for infectious virus by plaque assay on 3T6 cells. 
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Histology 
C57BL/6 and atc mice were infected via i.p. injection with 103 PFU MAV-1 in a volume 
of 100 µL. At 5 or 7 dpi, mice were euthanized CO2 asphyxiation and perfused with 10% 
formalin (3.7% formaldehyde in PBS), and organs were collected for histopathology. Organs 
(thymus, lung, heart, brain, liver, kidney, spleen, stomach, small intestine, colon/cecum) were 
immersion-fixed in 10% neutral buffered formalin for 24 hours, embedded in paraffin, and 
sectioned at 5 µm. Sections were stained with hematoxylin and eosin. The University of 
Michigan Comprehensive Cancer Center Research Histology and Immunoperoxidase Laboratory 
performed sectioning and staining. Slides were randomized and blinded for evaluation by a 
board-certified pathologist. 
 
Analysis of cytokine and chemokine levels  
50-100 mg of brain tissue were prepared in a 10% weight/volume solution with 
extraction buffer (50 mM Tris-HCl, 150 mM NaCl, 1% IGEPAL [Sigma I8896]) by adding the 
tissue and corresponding amount of buffer to bead beater tubes. They were then homogenized 
with sterile glass beads in a mini Beadbeater (Biospec Products) three times for 30 seconds, with 
a 10 second rest on ice between each homogenization. The tubes were then incubated on ice for 
30 minutes and then centrifuged at 2000 x g for 10 minutes at 4˚C to remove the remaining tissue 
debris. The supernatant was transferred to a new microcentrifuge tube and centrifuged again at 
20,000 x g for 20 minutes at 4˚C. The supernatant was transferred to a new tube. Protein 
concentrations were determined by a BCA assay (Pierce BCA Protein Assay Kit, Thermo 
Scientific #23227). The levels of cytokines and chemokines were measured in mouse brain 
lysates by ELISA by the University of Michigan Cancer Center Immunology Core. In each brain 
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lysate sample we measured IL-1a, IL-1b, IL-10, IP-10, IFNg, MCP-1, RANTES, KC, and 
TNFa. Plates were read using a MAGPIX plate reader and analyzed using xPONENT Software 
(Merck Millipore).  
 
Statistical analyses 
Data were analyzed with GraphPad Prism 7.0 software. For comparisons of qPCR 
analyses, the data were analyzed by individual Mann-Whitney tests. A value of P < 0.05 was 
considered significant.  
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Chapter IV 
Conclusions and Future Directions 
 
Protein kinase R (PKR) Chapter Review 
In Chapter II, we demonstrated that PKR has an antiviral role during mouse adenovirus 
type 1 (MAV-1) infection, because when PKR is mutated, viral replication in mouse embryonic 
fibroblasts (MEFs) is significantly higher compared to wild type MEFs. Analysis of global PKR 
steady-state protein levels during infection showed complete PKR depletion by 72 hours post 
infection (hpi) in multiple cell types, including immortalized and primary cells, with even faster 
kinetics in some. PKR steady-state mRNA levels and translation were not decreased by MAV-1 
infection, whereas proteasomal inhibition prevented PKR degradation. These data suggest that 
MAV-1 causes PKR to be proteasomally degraded at a post-translational level by an early viral 
protein, and we ruled out E1A and E3 as being required for this degradation (Fig. 4.1). 
 
Determining which early protein is responsible for PKR degradation during MAV-1 
infection 
The next obvious step is to determine which MAV-1 protein functioning early in 
infection is responsible for PKR degradation. Using mutant viruses, we have ruled out E1A and 
E3 as being required for PKR degradation. As described in the discussion of Chapter II, two  
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Figure 4.1 PKR degradation during MAV-1 infection. During MAV-1 infection, an as yet unidentified viral 
protein is produced by the virus and causes PKR to be degraded by the proteasome early in infection.
PKR
proteasome
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possibilities are E4 proteins, the homologs of human adenovirus (hAd) E4orf6 and E4orf3 (1). In 
hAd, E4orf6 interacts with another early hAd protein, E1B 55K, to participate in an E3 ligase 
complex that ubiquitinates and degrades p53 via proteasomal degradation (2, 3). When mouse 
p53 and MAV-1 E4orf6 and E1B 55K are introduced by transfection into human cells, all three 
proteins interact and mouse p53 is degraded (4). If MAV-1 E4orf6 and E1B 55K form a similar 
complex in mouse cells, it may also degrade PKR. We have preliminary evidence that mouse 
p53 is ubiquitinated in C57BL/6 MEFs during MAV-1 infection, which suggests that the mouse 
p53 degradation seen in human cells could be paralleled by degradation of endogenous mouse 
p53 and mouse PKR (mPKR) in mouse cells, mediated by MAV-1 E4orf6 and E1B 55K during 
infection.  
Another hAd E4 protein, E4orf3, causes proteasomal degradation of transcriptional 
intermediary factor 1g (5) and general transcription factor II-I (6) in a manner independent of 
hAd E4orf6 and E1B 55K. E4orf3	has SUMO E3 ligase and E4 elongase activity and induces 
sumoylation of general transcription factor II-I, leading to its proteasome-dependent degradation 
(6). MAV-1 E4orf3 may similarly have sumoylation activity that results ultimately in 
proteasome-dependent PKR degradation. All of the known targets of E4 degradation play a role 
in DNA damage response.  Because PKR also affects the DNA damage response (7), it is 
possible that E4 proteins are responsible for PKR degradation. 
Another possibility of a viral protein involved in PKR degradation is the protease 
encoded by MAV-1. The hAd protease is encapsidated in virions and proteolytically processes 
viral proteins IIIa, VI, VII, VIII, mu, and TP (8-11). However, we think it is unlikely that the 
MAV-1 protease degrades PKR, because we showed that UV-inactivated virus was unable to 
degrade PKR (Chapter II). We assume that UV treatment would not destroy the MAV-1 protease 
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activity, just as herpes simplex virus 1 (HSV-1) VP16 activity is not altered by UV-inactivation 
of HSV-1 (12), but we have not tested this directly.  
A way to screen these early viral proteins and others would be to transfect these proteins 
directly into mouse cells and assay for PKR protein levels in the absence of viral infection by 
immunoblot 24 to 48 hpi. We have constructs of FLAG-tagged E1A, E1B 19K, E1B 55K, E2 
DBP, E2 pTP, E3 class 1, E3 class 2, E3 class 3, E4orfa/b (E4orf6), E4orfa/c (E4orf3), E4orfd, 
and the proteinase. The proteins could be transfected individually or in combination, followed by 
immunoblot assay to obtain evidence of PKR degradation. If transfection into mouse cells proves 
to be difficult, the transfections could first be done in an easily transfectable human cell line as 
long as mPKR is also transfected in (we have a FLAG-tagged mPKR construct that can be used 
for this). 
If we see degradation with any of the constructs, then we will be able to determine the 
exact mechanism of PKR degradation by MAV-1. Once we know which early viral protein(s) are 
required for mPKR degradation, cells transfected with these viral proteins can be 
immunoprecipitated for the viral protein to identify any other host proteins that 
immunoprecipitate, suggesting they are recruited to degrade PKR. We can also mutate different 
regions of the viral protein to determine regions necessary for PKR binding or recruiting other 
proteins to degrade PKR. For example, we already have mutated versions of E4orf6 that prevent 
E4orf6 from recruiting Cul2 to the ligase complex normally formed by E4orf6 to degrade mouse 
p53 during infection (4). 
If we do not see degradation of PKR with any of the aforementioned constructs alone, we 
would test combinations of viral proteins, like E4orf6 and E1B 55K, to determine if multiple 
viral proteins are required for PKR degradation. We would also validate the transfection assay 
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system by transfecting the full MAV-1 genome into cells to determine whether PKR is degraded 
like it is during normal infection. Alternatively, we would immunoprecipitate PKR from 
MAV-1-infected cells that had been treated with MG132 to prevent PKR degradation, and use 
mass spectrometry to determine if any viral or host proteins are associating with PKR 
differentially during MAV-1 infection. This could point to proteins responsible for PKR 
degradation during MAV-1 infection. 
 
Effects of PKR phosphorylation on PKR degradation rate during MAV-1 infection 
 While we never immunoblotted for phospho-PKR during MAV-1 infection, all of my 
immunoblotting of mPKR showed up as doublet bands (Fig. 2.4A), except for the 
immunoblotting of the K271R SV40-MEFs, which expressed a kinase-dead PKR. The PKR 
signal produced in the K271R SV40-MEFs, when compared to the wild type SV40-MEFs, only 
showed a single band, at the position of the lower band of the doublet seen in the SV40-MEFs 
(Fig. 2.4C). This suggests that the upper band of the doublet is the phosphorylated form of PKR. 
In all cell types examined, this upper band was degraded at the same rate as the lower band. This 
is consistent with the degradation of PKR by Rift Valley Fever virus (RVFV) and 
foot-and-mouth disease virus, where phospho-PKR is degraded in addition to PKR during 
infection (13-16). However, in contrast, enterovirus A71 does not appear to cleave phospho-PKR 
during infection (17).  
While phospho-PKR levels decrease during MAV-1, RVFV, and foot-and-mouth disease 
virus infection, this does not prove that phospho-PKR itself is being degraded by the viruses. 
That is, perhaps phospho-PKR is first dephosphorylated to PKR and then PKR is degraded. 
When PKR becomes transautophosphorylated, many sites can be phosphorylated, but the main 
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sites that affect activity are S242, T255, T258, and T446 (18, 19). Modifying these residues to 
become chemically similar to a phosphorylated amino acid would create a phosphomimetic 
version of PKR. For example, replacing a serine or threonine with aspartic acid or glutamic acid, 
respectively, will chemically mimic phosphoserine or phosphothreonine (20). To determine 
whether phosphorylation protects PKR from being degraded, PKR-/- MEFs could be transfected 
with a wild type mPKR construct or a phosphomimetic mPKR construct, and degradation of 
each construct could be evaluated during MAV-1 infection by immunoblot. If the 
phosphomimetic PKR is degraded similarly to the wild type PKR, it would suggest that mPKR is 
degraded during MAV-1 infection regardless of its phosphorylation status. 
 
In vivo degradation of mPKR during MAV-1 infection 
 In Figure 2.2 of Chapter II, we showed that MAV-1 viral replication is higher in PKR-/- 
primary peritoneal macrophages and immortalized MEFs compared to wild type macrophages 
and MEFs. We also showed PKR degradation in a variety of other infected immortalized cell 
lines and in primary peritoneal macrophages (Fig. 2.4A). However, in vivo, PKR-/- mice had the 
same survival rate during MAV-1 infection as wild type mice (Fig. 2.3). To further characterize 
the in vivo effects of MAV-1 infection on PKR, it would be useful to analyze cells and organs 
from infected mice and determine whether PKR is degraded in vivo. Mock and MAV-1-infected 
wild type mice could have peritoneal macrophages, bone marrow macrophages, and organs 
removed and lysates from these cells or tissues could be analyzed by immunoblot for PKR 
protein levels. Determining if and in what cells PKR is degraded in vivo could provide evidence 
into why there is no difference in survival between PKR-/- and wild type mice during MAV-1 
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infection. The difference in survival could also be attributed to the incomplete knockout of PKR 
in these particular PKR-/- mice.  
 These mice are not complete PKR knockouts; MEFs from these mice produce a 
C-terminal fragment of PKR (Fig. 2.1) that still has kinase activity (21). However, this partial 
PKR fragment has not been characterized in vivo, so we do not know where or if it is expressed 
in mice and how much is produced. There currently are no complete PKR knockout mice in 
existence, so it would be useful to use CRISPR/Cas9 to create a complete or tissue-specific PKR 
knockout mouse to accurately measure the effect of PKR on survival of mice infected with 
MAV-1.  
 
MAV-1 replication kinetics in PKR-/- N-MEFs versus C-MEFs 
There are two different PKR-/- MEF lines: N-MEFs (pronounced N minus MEFs), which 
lack the double-stranded (ds) RNA binding domain but retain the kinase domain activity and the 
C-MEFs (pronounced C minus MEFs), which lack the kinase domain activity but retain the 
dsRNA binding domain activity (Fig. 2.1) (21). At 48 hpi, with MAV-1, the viral yield from the 
N-MEFs was nearly 4 times higher than the C-MEFs, but by 72 hpi the viral yields from both 
types of PKR-/- MEFs were similar to each other and significantly higher compared to wild type 
MEFs (Fig. 2.2A). This difference in viral replication kinetics between the two types of PKR-/- 
MEFs may be due to differences in expression level and activity of the PKR fragments 
reportedly produced by them (21). Although we have not assayed for PKR fragment production 
in our cells and mice, the fact that MAV-1 replicates to lower levels at intermediate times of 
infection in C-MEFs compared to N-MEFs suggests that presence of the dsRNA binding domain 
(present in the C-MEFs but not the N-MEFs) contributes more to PKR’s antiviral effects during 
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MAV-1 infection than the kinase domain. It would be useful to determine the levels of PKR 
fragment production and their activity levels in our hands in these MEFs to reinforce this 
conclusion.  
As proposed above, having complete PKR-/- MEFs to compare with wild type MEFs for 
MAV-1 replication would provide clearer information about the contribution of PKR to innate 
immunity during MAV-1 infection. It would be useful to create these MEFs directly, isolate 
them from a complete PKR-/- mouse if one is created, or from embryos if a complete PKR 
knockout mouse is embryonic lethal. If such PKR-/- MEFs are generated, constructs expressing 
the two main PKR domains (dsRNA binding and kinase domains) could be expressed in these 
PKR-/- MEFs during MAV-1 infection and the direct effects of each domain on MAV-1 
replication kinetics could be observed.  
 
Human PKR and MAV-1 
 Mouse PKR and human (hu) PKR share 58% amino acid identity and are 71% similar. 
Specifically, the dsRNA binding domains share 60% identity and are 75% similar, and the kinase 
domains share 67% identity and are 77% similar. When we infected PKR-/- MEFs reconstituted 
with FLAG-tagged huPKR variants, they were not degraded by MAV-1 infection, suggesting 
that MAV-1 does not degrade huPKR like it does mPKR (Fig. 2.5A). However, an important 
control missing from that experiment was PKR-/- MEFs reconstituted with FLAG-tagged mPKR 
to show it is degraded and that the FLAG tag is not likely to be inhibiting the degradation of 
huPKR. If FLAG-tagged mPKR is not degraded by MAV-1, that opens the possibility that 
MAV-1 actually could degrade huPKR. In that case, the PKR-/- MEFs should be reconstituted 
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with an untagged huPKR construct to confirm whether or not untagged huPKR can be degraded 
by MAV-1. 
If FLAG-tagged mPKR is degraded by MAV-1, that would confirm the conclusion that 
huPKR is not degraded by MAV-1. In that case, creating chimeric PKR constructs containing 
regions from mPKR and huPKR could help identify the region(s) of mPKR necessary for mPKR 
degradation by MAV-1. Constructs that swap mPKR and huPKR dsRNA binding domains or 
kinase domains would be obvious places to start. 
There were some interesting differences in MAV-1 replication in C-PKR-/- MEFs 
reconstituted to constitutively express FLAG-tagged full length, kinase-dead, or RNA binding-
deficient human PKR. MAV-1 replicated efficiently in the vector, full length, and RNA binding-
deficient huPKR lines, but replicated poorly in the kinase-dead huPKR line (Fig. 2.5B). 
Interestingly, the presence of full length huPKR doubled the amount of MAV-1 replication 
compared to the vector cell line, which contained no PKR at all, and this higher replication was 
reproduced in three separate experiments. These data suggest that the kinase domain of huPKR 
contributes significantly to MAV-1 infection. However, examining the immunoblot of the 
different huPKR variant expression levels (Fig. 2.5A), the amount of MAV-1 replication does 
seem to inversely correlate with the amount of huPKR present in each cell line. So while the 
virus replicated best in the full length huPKR cell line, that cell line also had the least amount of 
huPKR protein, and while the virus replicated the worst in the kinase-dead huPKR cell line, there 
was also the highest amount of huPKR protein. Thus, these differences in viral replication could 
be attributed to varying amounts of huPKR expressed in each cell line. 
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Ubiquitination of PKR during MAV-1 infection 
A signal for proteasomal degradation is the conjugation of ubiquitin to a protein (22, 23). 
Though we determined that PKR is being degraded by the proteasome during MAV-1 infection 
(Fig. 2.10), we were unable to show ubiquitination of PKR during MAV-1 infection (Fig. 2.12). 
This inability to demonstrate PKR ubiquitination could be explained if at any given moment 
there were only low levels of ubiquitinated PKR present in the cell. Perhaps increasing the time 
under MG132 treatment could increase the amounts of ubiquitinated proteins enough so that 
PKR ubiquitination could be. However, our inability to detect ubiquitinated PKR is consistent 
with a similar inability to identify PKR ubiquitination by RVFV NSs, even though NSs is known 
to recruit an E3 ligase to PKR (14).  
To completely rule out the possibility that PKR is ubiquitinated before being degraded by 
the proteasome during MAV-1 infection, PKR constructs could be made that mutate the lysine 
residues to prevent ubiquitination. These constructs could then be expressed in PKR-/- MEFs, 
infected with MAV-1, then analyzed by immunoblot for PKR. If PKR is still degraded during 
infection even with the ubiquitination sites mutated, it would suggest that PKR is being degraded 
by the proteasome independent of ubiquitin. This ubiquitin-independent method could involve 
intrinsic disordered regions of PKR or binding of regulating proteins to PKR that target proteins 
to the proteasome (24, 25). 
 
General control derepressible 2 (GCN2) Chapter Overview 
We have characterized the atc phenotype during MAV-1 infection. GCN2-/- mice and 
primary peritoneal macrophages have increased susceptibility to MAV-1 infection, but GCN2-/- 
MEFs do not (Fig. 3.2 and 3.3). The decrease in survival between GCN2-/- mice and wild type 
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mice is not explained by increased viremia or inflammatory disease, because there was no 
difference in viral yields or histology between any organs assayed from MAV-1-infected 
GCN2-/- or wild type mice (Fig. 3.4). There was, however, a difference in the cytokine and 
chemokine response to MAV-1 infection in the brains of GCN2-/- and wild type mice. At 7 days 
post infection (dpi), infected GCN2-/- mouse brains had higher levels of interleukin 1a, 
interleukin 1b, and interferon g compared to infected wild type mouse brains while at 8 dpi, 
infected wild type mouse brains had higher levels of interleukin 1a, interleukin 6, tumor necrosis 
factor a, KC, and monocyte chemoattractant protein-1 compared to GCN2-/- mouse brains (Fig. 
3.6). We also have preliminary data that in the serum at 8 dpi, increases in levels of interleukin 6 
and tumor necrosis factor a (relative to mock) were higher in MAV-1-infected atc mice than in 
MAV-1-infected wild type mice, whereas interleukin 1b and interferon g were not (data not 
shown). 
 
GCN2 activation by general control of amino-acid synthesis 1 (GCN1) 
 Using immunoblots to detect GCN2 or phospho-GCN2 proteins has proven difficult due 
to unreliable antibodies and low endogenous levels of GCN2. Our approach (in progress) is to 
epitope tag GCN2 to determine whether infection induces altered levels of GCN2 and phospho-
GCN2. In addition, it may be possible to analyze GCN1 levels by immunoblot as an indirect way 
of looking at GCN2 activation. GCN1 is an activator of GCN2 and also binds to ribosomes 
assisting in the transfer of uncharged tRNA to GCN2 (26). In yeast, GCN1 is required for GCN2 
activation during amino acid stress and UV irradiation, suggesting that GCN1 may be required 
for GCN2 activation in all scenarios. HSV-1 indirectly inhibits GCN2 by targeting GCN1 (27, 
28). HSV-1 glycoprotein H directly interacts with GCN1, changing its localization from the 
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cytoplasm to the nuclear rim, effectively sequestering GCN1 and not allowing it to assist in 
activating GCN2 during infection. We also have preliminary evidence showing that MAV-1 E1A 
interacts with GCN1 during infection from a GST pulldown screen using GST-tagged E1A 
(unpublished data, Fang and Spindler) (29). This result should be validated using our FLAG-
tagged E1A construct. FLAG-E1A could be transfected into C57BL/6 MEFs and 
immunoprecipitated after a period of time using the FLAG tag. Then the immunoprecipitates 
could be probed for GCN1. The reverse could also be done using GCN1 antibodies for the 
immunoprecipitation and E1A antibodies for E1A detection. If E1A associates with GCN1, it 
could be sequestering it from GCN2, as HSV glycoprotein H does in infection, or it could be 
preventing GCN1 from activating GCN2 to reduce GCN2 activity during MAV-1 infection. 
To determine whether MAV-1 affects GCN1 protein levels during infection, C57BL/6 
peritoneal macrophages and MEFs could be infected with MAV-1 or mock infected, and levels 
of GCN1 protein examined by immunoblot. If GCN1 levels decrease during infection, it would 
suggest that MAV-1 modulates GCN2 activation by interacting with GCN1 and reducing the 
amount of GCN1 present in the cell. If GCN1 levels stay the same or increase during infection, 
then it would be useful to compare the localization of GCN1 in mock and MAV-1-infected cells 
to determine whether MAV-1, possibly through E1A, is changing the location of GCN1 during 
infection. 
 
GCN2 activation by 25-hydroxycholesterol (25OHC) 
GCN2 activation by viruses can occur directly or indirectly. For example, mouse 
cytomegalovirus (MCMV) infection leads to the production of 25OHC, which triggers GCN2 
activation by reducing the levels of intracellular cysteine and/or by generating oxidative stress 
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(30). We showed that MAV-1 and MCMV had similar phenotypes in atc mice and cells, i.e., atc 
mice were more susceptible to MAV-1 and MCMV infection than wild type mice, and primary 
atc peritoneal macrophages also had higher viral replication of both viruses in comparison to 
wild type peritoneal macrophages (Fig. 3.2 and 3.3A) (31). However, atc and wild type 
immortalized MEFs showed no difference in viral replication with MAV-1 or MCMV (Fig. 
3.3B) (31). Since these phenotypes are similar for the two viruses, it is possible that MAV-1 also 
triggers the production of 25OHC, which could lead to GCN2 activation during infection. 
C57BL/6 peritoneal macrophages, bone marrow macrophages, and MEFs could be infected with 
MAV-1 or mock infected and 25OHC levels assayed by liquid chromatography/mass 
spectrophotometry at different times post infection. If 25OHC levels are increased during 
infection, that could indicate that MAV-1 is indirectly triggering GCN2 during infection. 
 
GCN2 activation through amino acid deprivation 
One of the main activators of GCN2 under non-infected conditions is amino acid 
starvation (26). Some viruses can trigger amino acid depletion during infection, such as yellow 
fever virus vaccine (YF-17D) (32) and HIV-1 (33). To determine whether MAV-1 activates 
GCN2 by causing amino acid deficiency during infection, C57BL/6 peritoneal macrophages and 
MEFs could be infected with MAV-1, and intracellular levels of free amino acids could be 
measured by liquid chromatography/mass spectrophotometry at different times post infection. If 
any levels of amino acids drop significantly, that could indicate that MAV-1 is indirectly 
triggering GCN2 during infection. 
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Phosphorylation of eukaryotic translation initiation factor 2a (eIF2a) 
 GCN2 and PKR are both eIF2a kinases, along with heme-regulated inhibitor kinase and 
PKR-like endoplasmic reticulum kinase. Thus, changes in GCN2 and PKR activation or activity 
during infection could have effects on eIF2a phosphorylation. Assaying eIF2a and eIF2a 
phosphorylation over the course of MAV-1 infection in wild type, PKR-/-, and GCN2-/- MEFs 
would enable determination of whether knocking out specific kinases has a significant impact on 
the amount of phosphorylated eIF2a, or whether the other three eIF2a kinases have redundant 
activity to reduce global cellular translation during MAV-1 infection. I have preliminary data in 
GCN2-/- peritoneal macrophages that very early in infection (2 hpi), there is a greater increase in 
eIF2a phosphorylation compared to MAV-1-infected wild type peritoneal macrophages at the 
same time point (Fig. 4.2). However, this was only a single experiment at an extremely early 
time point and only with GCN2-/- peritoneal macrophages. Repeating this experiment with more 
time points and PKR-/- peritoneal macrophages and both types of PKR-/- MEFs and GCN2-/- 
MEFs, and possibly creating double knockout PKR-/-and GCN2-/- MEFs, would provide more 
insight into the impact of knocking out these kinases on eIF2a phosphorylation. 
 
Effects of GCN2 deficiency on T-cell proliferation during MAV-1 infection 
 During viral infections, CD8+ T-cells can be activated by dendritic cells through cross-
presentation (34). Dendritic cells are antigen-presenting cells that can take up exogenous viral 
particles or virally infected cells and cross-present those antigens on their MHC class I 
molecules, activating CD8+ T-cells. The CD8+ T-cells can then destroy any other infected cells 
presenting those viral antigens. Autophagy plays a key role in antigen presentation, because 
dendritic cells and virally infected cells need to digest and present viral protein peptides on their 
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Figure 4.2 Atc peritoneal macrophages have a higher increase in phosphorylated eIF2⍺ during MAV-1 
infection. Wild-type (C57BL/6) and GCN2-/- (Atchoum) peritoneal macrophages were mock-infected (mock) 
or infected with MAV-1 at a MOI of 10 (MAV). Cell lysates were collected at 2 hours post infection and 
analyzed by immunoblot with antibodies for p-eIF2⍺, eIF2⍺, and actin. The blot was scanned and values 
were normalized to actin. The ratio of p-eIF2⍺ to eIF2⍺ and percent increase in eIF2⍺ phosphorylation in 
infected cells is shown below each line. Blot represents a single experiment.
p-eIF2⍺
eIF2⍺
actin
Ratio of p-eIF2⍺ to eIF2⍺:                               1.05    1.35    0.59   0.88
Percent increase in eIF2⍺ phosphorylation:                29%              49% 
mock  MAV  mock   MAV
C57BL/6       Atchoum
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MHC class I or class II molecules in order to signal CD8+ and CD4+ T-cells, respectively, to the 
presence of virus (35). In GCN2-/- dendritic cells incubated with YF-17D, autophagy was 
reduced compared to wild type dendritic cells (32). GCN2-/- mice immunized with YF-17D also 
showed a reduction in the proliferation of CD8+ and CD4+ YF-17D-specific T-cells, suggesting 
that GCN2 plays a role in promoting antigen cross presentation and priming secondary immunity 
during YF-17D immunization.  
 To determine if autophagy is disrupted in MAV-1-infected GCN2-/- dendritic cells, 
GCN2-/- dendritic cells or macrophages could be infected or mock infected, and levels of 
autophagy markers, like LC3 and Atg5, could be measured by immunoblot. If autophagy is 
impaired in infected GCN2-/- cells, this would suggest that antigen presentation may not be 
happening effectively in GCN2-/- animals during infection. Measuring CD8+- and CD4+-specific 
T-cells in the organs of GCN2-/- mice infected with MAV-1 by flow cytometry would provide 
additional insight into the immune response mounted by GCN2-/- mice during MAV-1 infection. 
 
Cell-type specific effects of GCN2 
In Chapter III, we showed that GCN2-/- mice and primary peritoneal macrophages have 
increased susceptibility to MAV-1 infection, but GCN2-/- MEFs do not (Fig. 3.2 and 3.3). This 
suggests that the antiviral role of GCN2 during MAV-1 infection may be cell-type specific. To 
further characterize how GCN2 deficiency affects immune and hematopoietic cells, four types of 
bone marrow chimeric mice (wild type bone marrow transplanted into wild type mice [wt®wt], 
wt®atc, atc®wt, and atc®atc) could be created. After reconstitution, the mice could be 
infected with MAV-1 and survival, viral load, cytokines and chemokine levels, and 
inflammatory responses would be measured. If GCN2 plays a critical antiviral role in this 
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compartment, wild type mice reconstituted with atc hematopoietic cells would have a decreased 
survival compared to mice reconstituted with wild type hematopoietic cells. 
 
Conclusions 
 PKR and GCN2 are both eIF2a kinases that function to phosphorylate eIF2a in response 
to specific stressors. This in turn leads to a reduction in global cellular translation, a cellular 
antiviral response that reduces viral protein synthesis. We know that MAV-1 does not induce 
host cell translation shutoff, indicating that in MAV-1 infected cells, cellular translation is intact 
(36). We also now know that MAV-1 degrades PKR during infection, reducing the number of 
active eIF2a kinases to three. Determining whether GCN2 or even PKR-like endoplasmic 
reticulum kinase is activated during MAV-1 infection and how MAV-1 interacts with GCN2 
during infection would provide information on the potential redundancies to maintain eIF2a 
phosphorylation during MAV-1 infection in spite of PKR degradation and the interplay between 
eIF2a kinases and MAV-1. It is possible that there is more crosstalk between the PKR and 
GCN2 pathways than previously studied, and this could have implications beyond immunity in 
viral infection. 
 In this work, we have shown a novel mechanism for PKR inhibition in DNA viruses. 
PKR is degraded by the proteasome during MAV-1 infection, and the virus mediates this 
degradation through an early viral protein. Determining which viral protein is responsible for 
PKR degradation will provide further insight into innate immune evasion by DNA viruses, and 
may help to identify other DNA viruses that could degrade PKR during infection. We have also 
shown that GCN2-/- mice and primary peritoneal macrophages are more susceptible to MAV-1 
infection compared to wild type mice. Also, brain cytokines and chemokines are altered in 
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GCN2-/- mice during infection, showing that GCN2 could be an important antiviral response 
during DNA virus infection. Determining how GCN2 is triggered during MAV-1 infection and 
whether the virus has any mechanism to inhibit that activation could provide insight into how 
GCN2 is playing an antiviral role in DNA virus infection. 
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